WO2019059302A1 - 安定性に優れるテリパラチド含有液状医薬組成物 - Google Patents
安定性に優れるテリパラチド含有液状医薬組成物 Download PDFInfo
- Publication number
- WO2019059302A1 WO2019059302A1 PCT/JP2018/034887 JP2018034887W WO2019059302A1 WO 2019059302 A1 WO2019059302 A1 WO 2019059302A1 JP 2018034887 W JP2018034887 W JP 2018034887W WO 2019059302 A1 WO2019059302 A1 WO 2019059302A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- component
- salt
- liquid pharmaceutical
- teriparatide
- pharmaceutical preparation
- Prior art date
Links
- 239000007788 liquid Substances 0.000 title claims abstract description 340
- OGBMKVWORPGQRR-UMXFMPSGSA-N teriparatide Chemical compound C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1N=CNC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CNC=N1 OGBMKVWORPGQRR-UMXFMPSGSA-N 0.000 title claims abstract description 256
- 108010049264 Teriparatide Proteins 0.000 title claims abstract description 236
- 229960005460 teriparatide Drugs 0.000 title claims abstract description 220
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 45
- 239000000825 pharmaceutical preparation Substances 0.000 claims abstract description 299
- 150000003839 salts Chemical class 0.000 claims abstract description 266
- 239000000872 buffer Substances 0.000 claims description 97
- 238000000034 method Methods 0.000 claims description 92
- 238000002360 preparation method Methods 0.000 claims description 60
- CKLJMWTZIZZHCS-REOHCLBHSA-N aspartic acid group Chemical group N[C@@H](CC(=O)O)C(=O)O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 claims description 54
- 230000015572 biosynthetic process Effects 0.000 claims description 43
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims description 39
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 claims description 37
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 35
- 239000004615 ingredient Substances 0.000 claims description 32
- 238000011188 deamidation reaction Methods 0.000 claims description 30
- FFEARJCKVFRZRR-BYPYZUCNSA-N L-methionine Chemical compound CSCC[C@H](N)C(O)=O FFEARJCKVFRZRR-BYPYZUCNSA-N 0.000 claims description 29
- 239000002253 acid Substances 0.000 claims description 28
- 239000004033 plastic Substances 0.000 claims description 28
- 229920003023 plastic Polymers 0.000 claims description 28
- 125000000613 asparagine group Chemical group N[C@@H](CC(N)=O)C(=O)* 0.000 claims description 27
- 238000006317 isomerization reaction Methods 0.000 claims description 24
- 229930182817 methionine Natural products 0.000 claims description 24
- 159000000000 sodium salts Chemical class 0.000 claims description 23
- 230000001629 suppression Effects 0.000 claims description 23
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 22
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 22
- 159000000007 calcium salts Chemical class 0.000 claims description 22
- 159000000003 magnesium salts Chemical class 0.000 claims description 22
- 235000010355 mannitol Nutrition 0.000 claims description 22
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims description 21
- 229920000858 Cyclodextrin Polymers 0.000 claims description 21
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 claims description 21
- BVKZGUZCCUSVTD-UHFFFAOYSA-L Carbonate Chemical compound [O-]C([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-L 0.000 claims description 20
- 241000894007 species Species 0.000 claims description 20
- 239000011780 sodium chloride Substances 0.000 claims description 19
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 18
- 239000007800 oxidant agent Substances 0.000 claims description 17
- JHJLBTNAGRQEKS-UHFFFAOYSA-M sodium bromide Chemical compound [Na+].[Br-] JHJLBTNAGRQEKS-UHFFFAOYSA-M 0.000 claims description 17
- 239000011521 glass Substances 0.000 claims description 16
- 229920001450 Alpha-Cyclodextrin Polymers 0.000 claims description 15
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 claims description 15
- HFHDHCJBZVLPGP-RWMJIURBSA-N alpha-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO HFHDHCJBZVLPGP-RWMJIURBSA-N 0.000 claims description 15
- 229940043377 alpha-cyclodextrin Drugs 0.000 claims description 15
- BUUKFBVDKSFMHN-LKMAISLMSA-N parathar acetate Chemical compound CC(O)=O.C([C@H](NC(=O)[C@H](CCSC)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)CO)C(C)C)[C@@H](C)CC)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CN=CN1 BUUKFBVDKSFMHN-LKMAISLMSA-N 0.000 claims description 15
- 229960000338 teriparatide acetate Drugs 0.000 claims description 15
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 claims description 14
- 239000001116 FEMA 4028 Substances 0.000 claims description 13
- ONIBWKKTOPOVIA-BYPYZUCNSA-N L-Proline Chemical compound OC(=O)[C@@H]1CCCN1 ONIBWKKTOPOVIA-BYPYZUCNSA-N 0.000 claims description 13
- 229930182821 L-proline Natural products 0.000 claims description 13
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 claims description 13
- 235000011175 beta-cyclodextrine Nutrition 0.000 claims description 13
- 229960004853 betadex Drugs 0.000 claims description 13
- 229960002429 proline Drugs 0.000 claims description 13
- 239000003795 chemical substances by application Substances 0.000 claims description 12
- 239000001509 sodium citrate Substances 0.000 claims description 12
- SNEIUMQYRCDYCH-LURJTMIESA-N N(alpha)-acetyl-L-arginine Chemical compound CC(=O)N[C@H](C(O)=O)CCCNC(N)=N SNEIUMQYRCDYCH-LURJTMIESA-N 0.000 claims description 11
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 claims description 11
- 229910001629 magnesium chloride Inorganic materials 0.000 claims description 11
- 125000001360 methionine group Chemical group N[C@@H](CCSC)C(=O)* 0.000 claims description 11
- 235000017281 sodium acetate Nutrition 0.000 claims description 11
- HRXKRNGNAMMEHJ-UHFFFAOYSA-K trisodium citrate Chemical compound [Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O HRXKRNGNAMMEHJ-UHFFFAOYSA-K 0.000 claims description 11
- 229940038773 trisodium citrate Drugs 0.000 claims description 11
- 239000001632 sodium acetate Substances 0.000 claims description 10
- KWTQSFXGGICVPE-UHFFFAOYSA-N 2-amino-5-(diaminomethylideneamino)pentanoic acid;hydron;chloride Chemical compound Cl.OC(=O)C(N)CCCN=C(N)N KWTQSFXGGICVPE-UHFFFAOYSA-N 0.000 claims description 9
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- BVHLGVCQOALMSV-JEDNCBNOSA-N L-lysine hydrochloride Chemical compound Cl.NCCCC[C@H](N)C(O)=O BVHLGVCQOALMSV-JEDNCBNOSA-N 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 9
- 238000007920 subcutaneous administration Methods 0.000 claims description 9
- 229960002885 histidine Drugs 0.000 claims description 8
- -1 teriparatide salt Chemical class 0.000 claims description 8
- KIIBBJKLKFTNQO-WHFBIAKZSA-N 5-hydroxyectoine Chemical compound CC1=N[C@H](C(O)=O)[C@@H](O)CN1 KIIBBJKLKFTNQO-WHFBIAKZSA-N 0.000 claims description 7
- 229930195725 Mannitol Natural products 0.000 claims description 7
- DZTHIGRZJZPRDV-UHFFFAOYSA-N N-acetyltryptophan Chemical compound C1=CC=C2C(CC(NC(=O)C)C(O)=O)=CNC2=C1 DZTHIGRZJZPRDV-UHFFFAOYSA-N 0.000 claims description 7
- CKLJMWTZIZZHCS-REOHCLBHSA-L aspartate group Chemical group N[C@@H](CC(=O)[O-])C(=O)[O-] CKLJMWTZIZZHCS-REOHCLBHSA-L 0.000 claims description 7
- 229960003237 betaine Drugs 0.000 claims description 7
- WQXNXVUDBPYKBA-YFKPBYRVSA-N ectoine Chemical compound CC1=[NH+][C@H](C([O-])=O)CCN1 WQXNXVUDBPYKBA-YFKPBYRVSA-N 0.000 claims description 7
- GDSRMADSINPKSL-HSEONFRVSA-N gamma-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO GDSRMADSINPKSL-HSEONFRVSA-N 0.000 claims description 7
- 229940080345 gamma-cyclodextrin Drugs 0.000 claims description 7
- 239000000594 mannitol Substances 0.000 claims description 7
- ODLHGICHYURWBS-LKONHMLTSA-N trappsol cyclo Chemical compound CC(O)COC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](COCC(C)O)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)COCC(O)C)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1COCC(C)O ODLHGICHYURWBS-LKONHMLTSA-N 0.000 claims description 7
- 230000005764 inhibitory process Effects 0.000 claims description 5
- 125000000430 tryptophan group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C2=C([H])C([H])=C([H])C([H])=C12 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 4
- 229910017053 inorganic salt Inorganic materials 0.000 abstract description 18
- 230000000704 physical effect Effects 0.000 abstract description 4
- 235000002639 sodium chloride Nutrition 0.000 description 206
- 239000000203 mixture Substances 0.000 description 98
- 238000009472 formulation Methods 0.000 description 88
- 239000000243 solution Substances 0.000 description 46
- 239000000654 additive Substances 0.000 description 35
- 238000003860 storage Methods 0.000 description 31
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 30
- 239000000126 substance Substances 0.000 description 30
- 230000000996 additive effect Effects 0.000 description 29
- 238000012360 testing method Methods 0.000 description 27
- 229960004452 methionine Drugs 0.000 description 23
- 230000006240 deamidation Effects 0.000 description 22
- 238000013112 stability test Methods 0.000 description 22
- 239000003814 drug Substances 0.000 description 19
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 19
- 229940079593 drug Drugs 0.000 description 15
- 238000006243 chemical reaction Methods 0.000 description 14
- 239000008215 water for injection Substances 0.000 description 13
- 238000002347 injection Methods 0.000 description 12
- 239000007924 injection Substances 0.000 description 12
- 108090000445 Parathyroid hormone Proteins 0.000 description 11
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
- 235000011054 acetic acid Nutrition 0.000 description 10
- 238000004128 high performance liquid chromatography Methods 0.000 description 10
- KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 9
- 102000003982 Parathyroid hormone Human genes 0.000 description 9
- 239000007864 aqueous solution Substances 0.000 description 9
- 239000000199 parathyroid hormone Substances 0.000 description 9
- 235000018102 proteins Nutrition 0.000 description 9
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- 238000010998 test method Methods 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 229960002337 magnesium chloride Drugs 0.000 description 8
- 238000010979 pH adjustment Methods 0.000 description 8
- 229960001319 parathyroid hormone Drugs 0.000 description 8
- 108090000765 processed proteins & peptides Proteins 0.000 description 8
- 230000002708 enhancing effect Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 238000005070 sampling Methods 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 235000019263 trisodium citrate Nutrition 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-VIFPVBQESA-N L-tryptophane Chemical compound C1=CC=C2C(C[C@H](N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-VIFPVBQESA-N 0.000 description 6
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- QIVBCDIJIAJPQS-UHFFFAOYSA-N Tryptophan Natural products C1=CC=C2C(CC(N)C(O)=O)=CNC2=C1 QIVBCDIJIAJPQS-UHFFFAOYSA-N 0.000 description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 239000000463 material Substances 0.000 description 6
- 239000003002 pH adjusting agent Substances 0.000 description 6
- 238000004806 packaging method and process Methods 0.000 description 6
- 235000017550 sodium carbonate Nutrition 0.000 description 6
- 239000004472 Lysine Substances 0.000 description 5
- 239000008351 acetate buffer Substances 0.000 description 5
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
- 150000001408 amides Chemical class 0.000 description 5
- 239000002585 base Substances 0.000 description 5
- 229960003646 lysine Drugs 0.000 description 5
- 230000014759 maintenance of location Effects 0.000 description 5
- 238000005259 measurement Methods 0.000 description 5
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 5
- 150000007524 organic acids Chemical class 0.000 description 5
- 239000000123 paper Substances 0.000 description 5
- 239000003755 preservative agent Substances 0.000 description 5
- 102000004196 processed proteins & peptides Human genes 0.000 description 5
- 235000019766 L-Lysine Nutrition 0.000 description 4
- ODKSFYDXXFIFQN-BYPYZUCNSA-N L-arginine Chemical compound OC(=O)[C@@H](N)CCCN=C(N)N ODKSFYDXXFIFQN-BYPYZUCNSA-N 0.000 description 4
- 229930064664 L-arginine Natural products 0.000 description 4
- 235000014852 L-arginine Nutrition 0.000 description 4
- WCUXLLCKKVVCTQ-UHFFFAOYSA-M Potassium chloride Chemical compound [Cl-].[K+] WCUXLLCKKVVCTQ-UHFFFAOYSA-M 0.000 description 4
- 150000001413 amino acids Chemical group 0.000 description 4
- 239000003125 aqueous solvent Substances 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 230000006641 stabilisation Effects 0.000 description 4
- 238000011105 stabilization Methods 0.000 description 4
- 239000003381 stabilizer Substances 0.000 description 4
- 238000004885 tandem mass spectrometry Methods 0.000 description 4
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 description 3
- 101001135770 Homo sapiens Parathyroid hormone Proteins 0.000 description 3
- 101001135995 Homo sapiens Probable peptidyl-tRNA hydrolase Proteins 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000002378 acidificating effect Effects 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000003139 buffering effect Effects 0.000 description 3
- 125000000404 glutamine group Chemical group N[C@@H](CCC(N)=O)C(=O)* 0.000 description 3
- 102000058004 human PTH Human genes 0.000 description 3
- 238000007689 inspection Methods 0.000 description 3
- 230000007774 longterm Effects 0.000 description 3
- 230000007935 neutral effect Effects 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 229940071643 prefilled syringe Drugs 0.000 description 3
- 230000002335 preservative effect Effects 0.000 description 3
- 238000005057 refrigeration Methods 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 238000010254 subcutaneous injection Methods 0.000 description 3
- 239000007929 subcutaneous injection Substances 0.000 description 3
- 238000007910 systemic administration Methods 0.000 description 3
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 150000001242 acetic acid derivatives Chemical class 0.000 description 2
- VSCWAEJMTAWNJL-UHFFFAOYSA-K aluminium trichloride Chemical compound Cl[Al](Cl)Cl VSCWAEJMTAWNJL-UHFFFAOYSA-K 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 150000001510 aspartic acids Chemical class 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 150000004649 carbonic acid derivatives Chemical class 0.000 description 2
- 230000015556 catabolic process Effects 0.000 description 2
- 150000001860 citric acid derivatives Chemical class 0.000 description 2
- 238000011109 contamination Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 238000011049 filling Methods 0.000 description 2
- 235000019253 formic acid Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- RLSSMJSEOOYNOY-UHFFFAOYSA-N m-cresol Chemical compound CC1=CC=CC(O)=C1 RLSSMJSEOOYNOY-UHFFFAOYSA-N 0.000 description 2
- DHRRIBDTHFBPNG-UHFFFAOYSA-L magnesium dichloride hexahydrate Chemical compound O.O.O.O.O.O.[Mg+2].[Cl-].[Cl-] DHRRIBDTHFBPNG-UHFFFAOYSA-L 0.000 description 2
- 235000019799 monosodium phosphate Nutrition 0.000 description 2
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 238000007254 oxidation reaction Methods 0.000 description 2
- 238000009512 pharmaceutical packaging Methods 0.000 description 2
- 239000001103 potassium chloride Substances 0.000 description 2
- 235000011164 potassium chloride Nutrition 0.000 description 2
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 2
- GEHJYWRUCIMESM-UHFFFAOYSA-L sodium sulfite Chemical compound [Na+].[Na+].[O-]S([O-])=O GEHJYWRUCIMESM-UHFFFAOYSA-L 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- KZNICNPSHKQLFF-UHFFFAOYSA-N succinimide Chemical compound O=C1CCC(=O)N1 KZNICNPSHKQLFF-UHFFFAOYSA-N 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- 229940043375 1,5-pentanediol Drugs 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- BDKLKNJTMLIAFE-UHFFFAOYSA-N 2-(3-fluorophenyl)-1,3-oxazole-4-carbaldehyde Chemical compound FC1=CC=CC(C=2OC=C(C=O)N=2)=C1 BDKLKNJTMLIAFE-UHFFFAOYSA-N 0.000 description 1
- QTWJRLJHJPIABL-UHFFFAOYSA-N 2-methylphenol;3-methylphenol;4-methylphenol Chemical compound CC1=CC=C(O)C=C1.CC1=CC=CC(O)=C1.CC1=CC=CC=C1O QTWJRLJHJPIABL-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- LSNNMFCWUKXFEE-UHFFFAOYSA-M Bisulfite Chemical compound OS([O-])=O LSNNMFCWUKXFEE-UHFFFAOYSA-M 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 101800004419 Cleaved form Proteins 0.000 description 1
- 208000005156 Dehydration Diseases 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- FFEARJCKVFRZRR-UHFFFAOYSA-N L-Methionine Natural products CSCCC(N)C(O)=O FFEARJCKVFRZRR-UHFFFAOYSA-N 0.000 description 1
- 229930195722 L-methionine Natural products 0.000 description 1
- COLNVLDHVKWLRT-QMMMGPOBSA-N L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=CC=C1 COLNVLDHVKWLRT-QMMMGPOBSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 229920002701 Polyoxyl 40 Stearate Polymers 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- DWAQJAXMDSEUJJ-UHFFFAOYSA-M Sodium bisulfite Chemical compound [Na+].OS([O-])=O DWAQJAXMDSEUJJ-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 239000003513 alkali Substances 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- AZDRQVAHHNSJOQ-UHFFFAOYSA-N alumane Chemical class [AlH3] AZDRQVAHHNSJOQ-UHFFFAOYSA-N 0.000 description 1
- 235000019270 ammonium chloride Nutrition 0.000 description 1
- 150000003863 ammonium salts Chemical class 0.000 description 1
- 229940009098 aspartate Drugs 0.000 description 1
- 235000019445 benzyl alcohol Nutrition 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 210000004899 c-terminal region Anatomy 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- AXCZMVOFGPJBDE-UHFFFAOYSA-L calcium dihydroxide Chemical compound [OH-].[OH-].[Ca+2] AXCZMVOFGPJBDE-UHFFFAOYSA-L 0.000 description 1
- 239000000920 calcium hydroxide Substances 0.000 description 1
- 229910001861 calcium hydroxide Inorganic materials 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000004359 castor oil Substances 0.000 description 1
- 235000019438 castor oil Nutrition 0.000 description 1
- 239000007795 chemical reaction product Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 229930003836 cresol Natural products 0.000 description 1
- 238000000354 decomposition reaction Methods 0.000 description 1
- 230000018044 dehydration Effects 0.000 description 1
- 238000006297 dehydration reaction Methods 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 229940119744 dextran 40 Drugs 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000002526 disodium citrate Substances 0.000 description 1
- 235000019262 disodium citrate Nutrition 0.000 description 1
- CEYULKASIQJZGP-UHFFFAOYSA-L disodium;2-(carboxymethyl)-2-hydroxybutanedioate Chemical compound [Na+].[Na+].[O-]C(=O)CC(O)(C(=O)O)CC([O-])=O CEYULKASIQJZGP-UHFFFAOYSA-L 0.000 description 1
- 238000010494 dissociation reaction Methods 0.000 description 1
- 230000005593 dissociations Effects 0.000 description 1
- 238000004090 dissolution Methods 0.000 description 1
- 238000004821 distillation Methods 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 239000002158 endotoxin Substances 0.000 description 1
- BEFDCLMNVWHSGT-UHFFFAOYSA-N ethenylcyclopentane Chemical compound C=CC1CCCC1 BEFDCLMNVWHSGT-UHFFFAOYSA-N 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229940053641 forteo Drugs 0.000 description 1
- 239000012634 fragment Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 229960001031 glucose Drugs 0.000 description 1
- 235000001727 glucose Nutrition 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 1
- 150000004687 hexahydrates Chemical class 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229960001375 lactose Drugs 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 235000018977 lysine Nutrition 0.000 description 1
- 229940050906 magnesium chloride hexahydrate Drugs 0.000 description 1
- VTHJTEIRLNZDEV-UHFFFAOYSA-L magnesium dihydroxide Chemical compound [OH-].[OH-].[Mg+2] VTHJTEIRLNZDEV-UHFFFAOYSA-L 0.000 description 1
- 239000000347 magnesium hydroxide Substances 0.000 description 1
- 229910001862 magnesium hydroxide Inorganic materials 0.000 description 1
- 229960002160 maltose Drugs 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 239000008155 medical solution Substances 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- HWPKGOGLCKPRLZ-UHFFFAOYSA-M monosodium citrate Chemical compound [Na+].OC(=O)CC(O)(C([O-])=O)CC(O)=O HWPKGOGLCKPRLZ-UHFFFAOYSA-M 0.000 description 1
- 239000002524 monosodium citrate Substances 0.000 description 1
- 235000018342 monosodium citrate Nutrition 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 150000002894 organic compounds Chemical class 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- COLNVLDHVKWLRT-UHFFFAOYSA-N phenylalanine Natural products OC(=O)C(N)CC1=CC=CC=C1 COLNVLDHVKWLRT-UHFFFAOYSA-N 0.000 description 1
- 239000008363 phosphate buffer Substances 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920005862 polyol Polymers 0.000 description 1
- 150000003077 polyols Chemical class 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229940099429 polyoxyl 40 stearate Drugs 0.000 description 1
- 150000007519 polyprotic acids Polymers 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- XAEFZNCEHLXOMS-UHFFFAOYSA-M potassium benzoate Chemical compound [K+].[O-]C(=O)C1=CC=CC=C1 XAEFZNCEHLXOMS-UHFFFAOYSA-M 0.000 description 1
- 238000004321 preservation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000013772 propylene glycol Nutrition 0.000 description 1
- 239000002510 pyrogen Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 239000012488 sample solution Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000000741 silica gel Substances 0.000 description 1
- 229910002027 silica gel Inorganic materials 0.000 description 1
- 229940087562 sodium acetate trihydrate Drugs 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 235000011083 sodium citrates Nutrition 0.000 description 1
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 1
- 235000010267 sodium hydrogen sulphite Nutrition 0.000 description 1
- 229940001584 sodium metabisulfite Drugs 0.000 description 1
- 235000010262 sodium metabisulphite Nutrition 0.000 description 1
- 229940001482 sodium sulfite Drugs 0.000 description 1
- 235000010265 sodium sulphite Nutrition 0.000 description 1
- 235000010199 sorbic acid Nutrition 0.000 description 1
- 239000004334 sorbic acid Substances 0.000 description 1
- 229940075582 sorbic acid Drugs 0.000 description 1
- 229960002920 sorbitol Drugs 0.000 description 1
- 239000006076 specific stabilizer Substances 0.000 description 1
- 229910001220 stainless steel Inorganic materials 0.000 description 1
- 239000010935 stainless steel Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 229960002317 succinimide Drugs 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 229960004793 sucrose Drugs 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 239000012929 tonicity agent Substances 0.000 description 1
- 238000011200 topical administration Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 229940074410 trehalose Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000012856 weighed raw material Substances 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
- A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
- A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/29—Parathyroid hormone, i.e. parathormone; Parathyroid hormone-related peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/40—Cyclodextrins; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
Definitions
- the present invention relates to a liquid pharmaceutical preparation containing teriparatide or a salt thereof.
- PTH parathyroid hormone
- calcitonins and vitamin Ds is a hormone involved in regulating blood calcium levels.
- PTH peptides which are physiologically active equivalents of natural forms of PTH, PTH peptide-containing lyophilized preparations and PTH peptide-containing solutions are also known.
- An object of the present invention is to provide a liquid pharmaceutical preparation containing teriparatide or a salt thereof having good physical properties. More specifically, the subject of the present invention is 1) the liquid pharmaceutical preparation in which the formation of a deamidated form of teriparatide or a salt thereof is suppressed, 2) the formation of an aspartic acid isomer of a teriparatide or a salt thereof. The present invention is to provide the liquid pharmaceutical preparation in which 3) the long-term stable liquid pharmaceutical preparation, and 4) the liquid pharmaceutical preparation in which the formation of oxidized form of teriparatide or its salt is suppressed.
- the subject of the present invention is also 5) Test methods using teriparatide analogues, presence of teriparatide analogues as indicators, liquid pharmaceutical preparations containing high purity teriparatide or its salts in which the content of teriparatide analogues is reduced It is to provide.
- liquid pharmaceutical preparation of the present invention contains at least one inorganic salt and / or organic salt. Furthermore, one aspect of the liquid pharmaceutical preparation of the present invention is that its pH is in a predetermined range (eg, 3.0 to 5.0). In such liquid pharmaceutical preparations, the formation of a deamidated form of teriparatide or a salt thereof can be suppressed.
- liquid pharmaceutical preparation of the present invention contains at least one inorganic salt and / or organic salt.
- the pH is in a predetermined range (eg, 3.0 to 5.0). In such liquid pharmaceutical preparations, the formation of aspartate isomer of teriparatide or a salt thereof can be suppressed.
- liquid pharmaceutical preparation of the present invention is that its pH is in a predetermined range (eg, 4.0 to 5.0).
- a more specific embodiment is a preparation which is filled in a glass medical container, contains substantially no buffer, and has a pH in a predetermined range (eg, 4.0 to 5.0).
- the container is filled in a plastic medical container, substantially contains a buffer, further contains D-mannitol, and the pH thereof is within a predetermined range (eg, 4.0 to 5). 0).
- a specific additive eg, ⁇ -cyclodextrin
- Such liquid pharmaceutical formulations may be stable over time.
- One embodiment of the liquid pharmaceutical preparation of the present invention contains a predetermined amount of methionine (eg, teriparatide or a salt thereof and methionine in a mass ratio of 1: 0.5 to 1.0).
- methionine eg, teriparatide or a salt thereof and methionine in a mass ratio of 1: 0.5 to 1.0.
- formation of an oxidized form of teriparatide or a salt thereof eg, formation of oxidized teriparatide in which methionine residue at the eighth position from the N-terminus of teriparatide or a salt thereof is sulfoxidized
- One aspect of the liquid pharmaceutical preparation of the present invention contains mannitol.
- an oxidized form of teriparatide or a salt thereof eg, the formation of an oxidized form of a tryptophan residue at position 23 in teriparatide or a salt thereof
- the formation of an oxidized form of teriparatide or a salt thereof can be suppressed.
- One aspect of the present invention is the presence and / or presence of a specific teriparatide analog (eg, deamidated form, Asp isomerate), a high-quality liquid pharmaceutical preparation having a reduced content of the same analog, and the same analog It is a test
- a specific teriparatide analog eg, deamidated form, Asp isomerate
- a liquid pharmaceutical preparation comprising component 1 and component 2.
- Component 1) teriparatide or a salt thereof.
- Component 2) One or more salts selected from sodium salts, calcium salts and magnesium salts, and / or salts selected from hydrochloride, hydrobromide, acetate, citrate and carbonate 1
- a salt of a species or more (however, component 2 is a component different from component 1).
- component 2 is a component different from component 1).
- the liquid pharmaceutical formulation as described in said [1] whose pH is less than 5.0.
- Component 2) One or more salts selected from sodium salts, calcium salts and magnesium salts, and / or salts selected from hydrochloride, hydrobromide, acetate, citrate and carbonate 1 A salt of a species or more (however, component 2 is a component different from component 1).
- a liquid pharmaceutical preparation which is substantially free (however, the pH is less than 5.0).
- Component 2) One or more salts selected from sodium salts, calcium salts and magnesium salts, and / or salts selected from hydrochloride, hydrobromide, acetate, citrate and carbonate 1 A salt of a species or more (however, component 2 is a component different from component 1).
- a liquid pharmaceutical preparation containing Component 1 and Component 2, which is a buffer (however, when Component 1 is a teriparatide salt, a salt detached from Component 1 does not correspond to the buffer here).
- a liquid pharmaceutical preparation which does not substantially contain (however, the pH is 5.0 or more).
- Component 2) One or more salts selected from sodium salts, calcium salts and magnesium salts, and / or salts selected from hydrochloride, hydrobromide, acetate, citrate and carbonate 1 A salt of a species or more (however, component 2 is a component different from component 1).
- Ingredient 4) D-mannitol.
- a liquid pharmaceutical formulation containing ingredient 1 and ingredient 5. Component 1) teriparatide or a salt thereof.
- Component 5) L-proline, betaine, ectoin, hydroxyectoin, L-arginine hydrochloride, L-histidine, 2-hydroxypropyl- ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, One or more components selected from the group consisting of N-acetyl-arginine, L-lysine hydrochloride, and N-acetyl-DL-tryptophan.
- Component 5 is one or more components selected from the group consisting of ⁇ -cyclodextrin, ⁇ -cyclodextrin, N-acetyl-arginine, L-proline, L-arginine hydrochloride, and L-lysine hydrochloride.
- Component 2 is one or more salts selected from sodium chloride, calcium chloride, magnesium chloride, sodium bromide, sodium acetate, trisodium citrate and sodium carbonate according to the above [1] to [6]. Liquid pharmaceutical preparation. [15] The liquid pharmaceutical formulation as described in the above-mentioned [14], wherein component 2 is sodium chloride and / or trisodium citrate.
- Component 1) teriparatide or a salt thereof.
- Component 2) One or more salts selected from sodium salts, calcium salts and magnesium salts, and / or salts selected from hydrochloride, hydrobromide, acetate, citrate and carbonate 1 A salt of a species or more (however, component 2 is a component different from component 1).
- the suppression of the deamidation reaction is the suppression of the formation of a deamidated form of component 1 in which the asparagine residue in component 1 located at the 16th position from the N-terminus of component 1 is changed to an isoaspartic acid residue [ 25].
- Component 2 is at least one salt selected from sodium chloride, calcium chloride, magnesium chloride, sodium bromide, sodium acetate, trisodium citrate and sodium carbonate (however, component 2 is a component different from component 1)
- Component 1) teriparatide or a salt thereof.
- Component 2) One or more salts selected from sodium salts, calcium salts and magnesium salts, and / or salts selected from hydrochloride, hydrobromide, acetate, citrate and carbonate 1 A salt of a species or more (however, component 2 is a component different from component 1).
- Component 2 One or more salts selected from sodium salts, calcium salts and magnesium salts, and / or salts selected from hydrochloride, hydrobromide, acetate, citrate and carbonate 1 A salt of a species or more (however, component 2 is a component different from component 1).
- the suppression of the isomerization of aspartate residues is the suppression of the isomerization of aspartate residues of component 1 in which the aspartic acid residue located 30th from the N-terminus of component 1 is changed to an isoaspartic acid residue. The method according to [30] above.
- Component 2 is at least one salt selected from sodium chloride, calcium chloride, magnesium chloride, sodium bromide, sodium acetate, trisodium citrate and sodium carbonate (however, component 2 is a component different from component 1)
- Component 3 is not contained in the liquid pharmaceutical preparation, and the pH of the liquid pharmaceutical preparation is made to be more than 4.0 and not more than 5.0.
- a method comprising incorporating 1 and component 3 in a mass ratio of 1: 0.2 to 1.0, wherein the oxidized form of component 1 comprises a methionine residue at position 8 from the N-terminus of teriparatide
- a method which is a sulfoxidated teriparatide oxidized form or a salt thereof.
- Component 1) teriparatide or a salt thereof.
- Component 3) methionine.
- a method for suppressing the formation of an oxidized form of component 1 in a liquid pharmaceutical preparation containing component 1, comprising incorporating component 4 in the liquid pharmaceutical preparation, wherein the oxidized form of component 1 is N of component 1
- the salt to be released does not substantially correspond to the buffer here), and the method comprising bringing the pH of the liquid pharmaceutical preparation to more than 4.0 and not more than 5.0.
- Component 5 L-proline, betaine, ectoin, hydroxyectoin, L-arginine hydrochloride, L-histidine, 2-hydroxypropyl- ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, ⁇ -cyclodextrin, One or more components selected from the group consisting of N-acetyl-arginine, L-lysine hydrochloride and N-acetyl-DL-tryptophan.
- Component 5 is one or more components selected from the group consisting of ⁇ -cyclodextrin, ⁇ -cyclodextrin, N-acetyl-arginine, L-proline, L-arginine hydrochloride, and L-lysine hydrochloride [37 ] The method as described in. [39] An analogue of ingredient 1 wherein the asparagine residue present 16th from the N-terminus of ingredient 1 is changed to an isoaspartic acid residue, the other residues being identical to the corresponding residues of teriparatide . Component 1) teriparatide or a salt thereof.
- Component 1) teriparatide or a salt thereof.
- liquid pharmaceutical preparation containing teriparatide or a salt thereof excellent in physical properties is provided.
- Liquid pharmaceutical preparations provides, in one aspect, a liquid pharmaceutical formulation comprising component 1) teriparatide or a salt thereof, and component 2) at least one or more inorganic salts and / or organic salts.
- the present invention provides, as one aspect, a liquid pharmaceutical preparation containing component 1) teriparatide or a salt thereof, and having a pH in a predetermined range (eg, 3.0 to 5.0).
- the liquid pharmaceutical preparation wherein the mass ratio of component 1 to component 2 is 1:20 or 20 or more.
- the present invention includes, in one aspect, component 1) teriparatide or a salt thereof, and contains a specific additive. More preferred specific embodiments of the present invention according to these embodiments are listed below.
- Component 1) A liquid pharmaceutical preparation containing teriparatide or a salt thereof and component 3) methionine, wherein component 1: component 3 is 1: 0.2 to 1.0.
- Component 1) Liquid pharmaceutical formulation containing teriparatide or a salt thereof, and component 4) D-mannitol.
- Component 1) Teriparatide or a salt thereof, and Component 5) L-proline, betaine, ectoin, hydroxyectoin, L-arginine hydrochloride, L-histidine, 2-hydroxypropyl- ⁇ -cyclodextrin, ⁇ -cyclodextrin
- a liquid pharmaceutical preparation comprising one or more components selected from the group consisting of ⁇ -cyclodextrin, ⁇ -cyclodextrin, N-acetyl-arginine, L-lysine hydrochloride and N-acetyl-DL-tryptophan.
- Liquid pharmaceutical preparation The form of the liquid pharmaceutical preparation of the present invention is not particularly limited as long as it is a liquid pharmaceutical preparation containing teriparatide or a salt thereof (component 1) described later.
- Examples include preparations for oral administration (internal use drugs) or preparations for parenteral administration, but preparations for parenteral administration are preferred.
- preparations for parenteral administration include preparations for topical administration such as external preparations and preparations for systemic administration such as injections, but preparations for systemic administration are preferable, and injections are particularly preferable.
- specific administration routes for systemic administration include intravenous administration, intramuscular administration, intradermal administration, subcutaneous administration and the like, and subcutaneous administration is preferable. That is, as the liquid pharmaceutical preparation of the present invention, preferably a liquid pharmaceutical preparation for subcutaneous administration or a liquid pharmaceutical preparation for injection can be exemplified, and most preferably, a liquid pharmaceutical preparation for subcutaneous injection can be exemplified.
- the “medicament” in the liquid pharmaceutical preparation means a drug used for the prevention / treatment / diagnosis of any disease to a mammal (human, monkey, rat, etc.).
- the solvent used for the liquid pharmaceutical preparation of the present invention is not particularly limited, and may be an aqueous solvent or a non-aqueous solvent, but is preferably an aqueous solvent. That is, the liquid pharmaceutical preparation of the present invention is preferably an aqueous pharmaceutical preparation.
- the liquid pharmaceutical preparation of the present invention is particularly an aqueous pharmaceutical preparation Is preferred, and may be prepared, for example, by water for injection or saline.
- the aqueous solvent may be selected from various components such as at least one or more of inorganic salts and / or organic salts (component 2), buffers, additives (components 3 to 6) described later without departing from the scope of the present invention. You may contain.
- human PTH (1-34) is composed of the first to 34th amino acid residues viewed from the N-terminal side in the amino acid sequence of human parathyroid hormone human PTH (1-84). It is a peptide shown by a partial amino acid sequence.
- teriparatide means free human PTH (1-34).
- Teriparatide can also be in the form of a salt.
- the teriparatide salt includes any salt formed by teriparatide and one or more volatile organic acids.
- volatile organic acids include trifluoroacetic acid, formic acid and acetic acid.
- the ratio of the free form teriparatide and the volatile organic acid to form a salt is not particularly limited as long as the salt is formed.
- acetic acid is preferable as the volatile organic acid. That is, as a salt of teriparatide in the present invention, teriparatide acetate can be preferably exemplified.
- teriparatide or a salt thereof is a peptide, it has its isoelectric point (pI).
- the measurement of pI can be performed by a method known per se (for example, a method using HPLC, electrophoresis or the like).
- the pI of teriparatide or a salt thereof (component 1) is known to be 8.3 to 8.4.
- the amount of teriparatide or a salt thereof (component 1) contained in the liquid pharmaceutical preparation of the present invention is not particularly limited, but the following can be preferably exemplified. That is, the lower limit is preferably 10 ⁇ g or more, and more preferably 20 ⁇ g or more, 25 ⁇ g or more, 27 ⁇ g or more, and further preferably 28 ⁇ g or more.
- the upper limit is preferably 100 ⁇ g or less, more preferably 50 ⁇ g or less, 40 ⁇ g or less, 35 ⁇ g or less, 30 ⁇ g or less, and further preferably 29 ⁇ g or less.
- the content of component 1 is preferably 28.2 ⁇ g or 29.2 ⁇ g.
- the content of component 1 can be 56.5 ⁇ g in terms of teriparatide.
- the teriparatide used is acetate
- the amount taking into account the amount of acetic acid can be exemplified, and in the case of teriparatide pentaacetate, the content of component 1 as teriparatide acetate is preferably 30.3 ⁇ g or 31.3 ⁇ g .
- the content of component 1 can be 60.6 ⁇ g as teriparatide acetate.
- the content per dose of teriparatide or a salt thereof (component 1) contained in the liquid pharmaceutical preparation of the present invention is not particularly limited, but the following can be preferably exemplified. That is, the lower limit is more preferably 25 ⁇ g or more, 27 ⁇ g or more, and further preferably 28 ⁇ g or more. The upper limit is more preferably 35 ⁇ g or less, 30 ⁇ g or less, and further preferably 29 ⁇ g or less. Among them, the dose per single dose of Component 1 is preferably 28.2 ⁇ g as teriparatide.
- the teriparatide used is acetate
- an amount considering the amount of acetic acid can be exemplified, and in the case of teriparatide pentaacetate, the content per ingredient of the component 1 is 30.3 ⁇ g as teriparatide acetate preferable.
- the concentration of teriparatide or a salt thereof (component 1) contained in the liquid pharmaceutical preparation of the present invention is not particularly limited, but the following can be preferably exemplified. That is, as teriparatide, the lower limit is preferably 50 ⁇ g / mL or more, and more preferably 70 ⁇ g / mL or more, 100 ⁇ g / mL or more, 100 ⁇ g / mL or more, 110 ⁇ g / mL or more, and further preferably 120 ⁇ g / mL or more .
- the upper limit is preferably 500 ⁇ g / mL or less, more preferably 250 ⁇ g / mL or less, less than 250 ⁇ g / mL, 200 ⁇ g / mL or less, 180 ⁇ g / mL or less, and further preferably 160 ⁇ g / mL or less.
- 141 ⁇ g / mL can be most preferably exemplified.
- the teriparatide or a salt thereof (component 1) contained in the liquid pharmaceutical preparation of the present invention can be produced by a method known per se (for example, the methods described in Non-Patent Documents 3 to 5 and the like).
- teriparatide or a salt thereof (component 1) is a teriparatide salt
- a salt formed by dissociation of the teriparatide salt in the liquid pharmaceutical preparation of the present invention is not regarded as a buffer according to the present invention.
- the same salt is not considered as "the at least one or more inorganic salt and / or organic salt (component 2)" according to the present invention.
- the liquid pharmaceutical preparation of the present invention preferably contains at least one or more inorganic salts and / or organic salts. In such a liquid pharmaceutical preparation, preferably, both deamidation of component 1 and aspartic acid residue isomerization can be suppressed.
- the inorganic salt means a salt formed by binding an inorganic acid with a base.
- hydrochloride, hydrobromide and bisulfite can be exemplified.
- sodium chloride, potassium chloride, ammonium chloride, calcium chloride, magnesium chloride, aluminum chloride, bromide Sodium and sodium bisulfite can be exemplified, and sodium chloride, calcium chloride, magnesium chloride and sodium bromide can be most preferably exemplified.
- the organic salt means a salt formed by combining an organic acid with a base.
- organic salts acetates, citrates and carbonates can be mentioned.
- sodium acetate, sodium citrate (monosodium citrate, disodium citrate and trisodium citrate), sodium carbonate can be preferably exemplified.
- sodium salt, potassium salt, ammonium salt, calcium salt, magnesium salt and aluminum salt can be preferably exemplified.
- the organic salt and the inorganic salt in the present invention may be anhydrous or may be hydrate.
- magnesium chloride is usually marketed as hexahydrate, and this can be used as it is as an inorganic salt in the present invention, or magnesium chloride anhydride obtained through dehydration treatment is used as an inorganic salt. You can also.
- magnesium chloride hydrate and “sodium acetate hydrate” mean “magnesium chloride hexahydrate” and “sodium acetate trihydrate”, respectively.
- At least one or more inorganic salts and / or organic salts are at least one or more inorganic salts, at least one or more inorganic salts and at least one or more organic salts, or at least one or more Means organic salt.
- One or more salts selected from sodium salts, calcium salts, and magnesium salts as at least one or more inorganic salts and / or organic salts, or hydrochlorides, hydrobromides, acetates, citrates And one or more salts selected from carbonates can be mentioned preferably, and sodium salt and / or citrate can be mentioned more preferably. More specifically, one or more salts selected from sodium chloride, calcium chloride, magnesium chloride, sodium bromide, sodium acetate, trisodium citrate and sodium carbonate can be mentioned more preferably.
- Non-Patent Document 8 the deamidation reaction of asparagine residues of small peptides is not affected by the ionic strength of the reaction solution (Abstract), and addition of sodium chloride to the reaction solution suppresses the deamidation reaction Not done (Table III) is disclosed. Moreover, in the literature to which Non-patent document 9 refers, it is also reported that the increase in ionic strength by sodium chloride addition accelerates the deamidation reaction (McKerrow and Robinson, 1971; Scotchler and Robinson, 1974; page 22553 left column) ).
- the addition of one or more inorganic salts and / or organic salts to the liquid pharmaceutical preparation suppresses the formation of the deamidated form of teriparatide or its salt (component 1) in the liquid pharmaceutical preparation. obtain. Further, in the present invention, by adding one or more inorganic salts and / or organic salts to a liquid pharmaceutical preparation, teriparatide or its salt (component 1) isomer isomer of an aspartic acid residue in the liquid pharmaceutical preparation. Production can be suppressed.
- the concentration is not particularly limited, but the lower limit is 250 ⁇ g / mL or more, 500 ⁇ g / mL or more, 1 mg / mL or more Alternatively, it is preferably 2 mg / mL or more, more preferably 3 mg / mL or more, and even more preferably 5.5 mg / mL or more.
- the upper limit is preferably 250 mg / mL or less, 100 mg / mL or less, or 25 mg / mL or less, and more preferably 11 mg / mL or less.
- the mass ratio of the teriparatide or its salt (component 1) (component 1: component 2) Is not particularly limited, but the lower limit is preferably 1: 5 or more, more preferably 1:10 or more, 1:15 or more, and even more preferably 1:20 or more. Most preferably, it is 35 or more.
- the upper limit is, for example, preferably 1: 500 or less, more preferably 1: 300 or less, and most preferably 1:80 or less.
- the “at least one or more inorganic salt and / or organic salt (component 2)” may be the same as or different from the components of the buffer described later.
- the buffer according to the present invention is not particularly limited as long as it can stabilize the pH of an aqueous solution and is generally used in the pharmaceutical field.
- Examples of the buffer according to the present invention include acetic acid, tartaric acid, lactic acid, citric acid, boric acid, phosphoric acid, carbonic acid and salts thereof. More specifically, acetic acid and sodium acetate, citric acid and trisodium citrate, sodium hydrogencarbonate and sodium carbonate, sodium dihydrogenphosphate and sodium dihydrogenphosphate can be exemplified.
- Such buffer may be included in the liquid pharmaceutical formulation of the present invention.
- a liquid pharmaceutical preparation substantially containing a buffer according to the present invention and further containing at least one inorganic salt and / or organic salt, teriparatide or a salt thereof in the preparation (component 1) Both the formation of the deamidated form of) and the formation of the aspartic acid residue isomerized form of component 1 can be suppressed.
- the liquid pharmaceutical preparation of the present invention may be a liquid pharmaceutical preparation substantially free of buffer, and among them, a liquid pharmaceutical preparation substantially free of acetate buffer is preferable.
- substantially does not contain the buffer, for example, when it is placed in a non-alkali glass container such as decomposition of teriparatide or its salt (component 1) and other additives, sulfur treatment, etc. Over time, such as alkaline elution, components of the drug solution and their reaction products, components dissolved in the drug solution from the container or container filled with drug solution, and various effects of the external environment during storage on the drug solution, etc. It means that the inclusion of a buffer whose pH fluctuation can not be suppressed is not regarded as inclusion.
- the buffer is not “substantially” contained in the liquid pharmaceutical preparation
- the case where a very small amount of buffer is contained in the liquid pharmaceutical preparation can be mentioned.
- the amount may vary depending on the buffer to be selected, but for example, even if a buffer having a concentration of 1 mM or less, preferably 0.5 mM or less, more preferably 0.1 mM or less is contained in the liquid pharmaceutical preparation, Is considered "substantially" not included in the liquid pharmaceutical formulation.
- the buffer is considered to be “substantially” not included in the liquid pharmaceutical formulation is the lower end of the same range or value and in the embodiment of the liquid pharmaceutical formulation of the present invention in which the pH is a specific range or a specific value.
- the inclusion of at least a buffer having no buffer capacity can be mentioned.
- the buffer in an embodiment of the liquid pharmaceutical preparation of the present invention having a pH of 4 to 5, a buffer having at least a buffering capacity in a pH range of 3 to 6 or a pH of 4.6
- the buffer when the buffer contains at least a buffer having no buffering capacity in the pH range of 3.6 to 5.6, the buffer is used for the liquid pharmaceutical preparation of the present invention. It is considered “substantially” not included.
- the buffer is considered to be “substantially” not included in the liquid pharmaceutical formulation
- the buffer has a pKa ⁇ 1
- the liquid pharmaceutical preparation contains a buffer which is not included or overlapped in the same pH range or value.
- the pKa of the acetate buffer (which is actually the pKa of acetic acid) is 4.76
- this ⁇ 1 is 3.76 to 5.76
- the pH is less than 3.76 or more than 5.76.
- the acetate buffer is considered to be "substantially” not included in the liquid pharmaceutical formulation, even if the liquid pharmaceutical formulation exhibits an acetate buffer.
- phosphoric acid is a polybasic acid and has three types of pKa (2.12, 7.21, 12.32), H 3 PO 4 , NaH 2 PO 4 , NaH 2 PO 4
- H 3 PO 4 a polybasic acid and has three types of pKa (2.12, 7.21, 12.32)
- NaH 2 PO 4 NaH 2 PO 4
- Na 3 PO 4 Each combination of Na 2 HPO 4 , Na 2 HPO 4 and Na 3 PO 4 will have buffering action in the individual pH range, but if the combination is not specifically stated, the above three pKa's
- the phosphate buffer is contained in the liquid pharmaceutical preparation even if the liquid pharmaceutical preparation does not include or overlap the specified pH range of ⁇ 1 for any of the pKa. Are considered not to be included.
- the conjugate base eg, sodium acetate of a weak acid (eg, acetic acid) in the liquid pharmaceutical preparation of the present invention is contained, but when the weak acid (eg, acetic acid) is not contained in the preparation, the conjugate is used.
- the base is not considered a buffer according to the invention.
- the same conjugate base corresponds to the "at least one or more inorganic salt and / or organic salt (component 2)" according to the present invention described above, the "at least one or more inorganic salt” according to the present invention And / or an organic salt (component 2) ".
- Additives Components 3 to 6
- the liquid pharmaceutical preparation of the present invention can also contain various additives.
- additives include solubilizers, stabilizers, tonicity agents, pH adjusters, preservatives (preservatives) and the like.
- solubilizers examples include propylene glycol, dipropylene glycol, pentylene glycol, polyethylene glycol, polyoxyethylene hydrogenated castor oil, polyoxyl 40 stearate, popidone, polysorbate 80 and the like.
- Examples of the tonicity agent according to the present invention include D-mannitol, sorbitol, glucose, glycerin, propylene glycol, sodium chloride, potassium chloride and the like.
- pH adjusters examples include dilute hydrochloric acid, sulfuric acid, phosphoric acid, sodium hydroxide, calcium hydroxide, magnesium hydroxide, triethanolamine and the like.
- preservative examples include methyl paraooxybenzoate, ethyl paraooxybenzoate, propyl paraooxybenzoate, sodium benzoate, phenol, cresol, sorbic acid, benzyl alcohol and the like.
- the hydrochloride, N-acetyl-DL-tryptophan and the like can be exemplified.
- L-proline, L-arginine or a hydrochloride thereof, ⁇ -cyclodextrin, ⁇ -cyclodextrin, L-lysine or a hydrochloride thereof, mannitol and methionine can be preferably exemplified, and ⁇ -cyclodextrin and ⁇ - Most preferred are cyclodextrin, D-mannitol and L-methionine.
- the content of the stabilizer according to the present invention is not particularly limited, but the content is about 0.1 to 1000 times (mass ratio) of the content of teriparatide or its salt (component 1) contained in the liquid pharmaceutical preparation of the present invention. Is preferred.
- Methionine (component 3) The liquid pharmaceutical preparation of the present invention can contain methionine.
- methionine When methionine is added to the liquid pharmaceutical preparation of the present invention, it is preferably contained 0.1 times (mass ratio) or more of the content of teriparatide or a salt thereof (component 1), 0.3 times or more, 0. More preferably, it is contained 5 times or more, or 0.7 times or more.
- the upper limit of the amount of methionine added is not particularly limited as long as it is dissolved in the liquid pharmaceutical preparation of the present invention, but for example, it may preferably be 10.0 times or less or 5.0 times or less. Can be further preferably exemplified, and 1.0 times or less can be most preferably exemplified.
- the amount of methionine added to the liquid pharmaceutical preparation of the present invention can be preferably exemplified by about 0.5 to 1.0 times (mass ratio to teriparatide or salt).
- D-mannitol (component 4): D-mannitol can be contained in the liquid pharmaceutical preparation of the present invention.
- the content of D-mannitol is not particularly limited, but it is preferable that the D-mannitol content is about 10 to 1000 times (mass ratio) the content of teriparatide or a salt thereof (component 1).
- the liquid pharmaceutical preparation of the present invention includes L-proline, betaine, ectoin, hydroxyectoin, L-arginine or its hydrochloride, L-histidine or its hydrochloride, 2-hydroxypropyl- ⁇ -cyclodextrin, ⁇ -cyclodextrin , One or more components (component 5) selected from the group consisting of ⁇ -cyclodextrin, ⁇ -cyclodextrin, L-lysine or a hydrochloride thereof, N-acetyl-DL-tryptophan, and N-acetyl-arginine You can Component 5 includes one or more selected from the group consisting of ⁇ -cyclodextrin, ⁇ -cyclodextrin, N-acetyl-arginine, L-lysine or a hydrochloride thereof, L-proline, and L-arginine or a hydrochloride thereof It is preferable that it is
- component 5 When component 5 is to be contained in a liquid pharmaceutical preparation, it is preferable that the liquid pharmaceutical preparation contains a buffer, for example, it is preferable that an acetic acid buffer is contained.
- a buffer for example, it is preferable that an acetic acid buffer is contained.
- the pH of the liquid pharmaceutical preparation is not particularly limited, and may be in a suitable range described later.
- the pH of the liquid pharmaceutical preparation in the present invention is not particularly limited.
- the pH of the liquid pharmaceutical preparation of the present invention may preferably be as follows. That is, it can be neutral or acidic (pH is 8.0 or less), and the lower limit is, for example, 3.0 or more, 3.6 or more, 3.8 or more, 4.0 or more, 4.0 or more, 4 It is preferable to set it as 1 or more, 4.2 or more, or 4.4 or more.
- the upper limit may be, for example, 7.0 or less, less than 7.0, 6.0 or less, 5.0 or less, less than 5.0, 4.9 or less, 4.8 or less, or 4.6 or less preferable.
- PTH and PTH fragments are used as an aqueous solution agent, their storage stability is poor, and so conventionally used as a freeze-dried preparation, or using a specific stabilizer or preservative such as polyol or m-cresol. It has been practiced to use an aqueous solution.
- a buffer to the preparation to reduce pH fluctuation when it is made into a liquid pharmaceutical preparation (non- See Patent Document 2 and Patent Document 4 etc.).
- the buffer in a liquid pharmaceutical preparation containing teriparatide or a salt thereof (component 1), is substantially contained in the preparation by specifying the pH range within the above-mentioned suitable range. It can be made into the liquid pharmaceutical preparation which shows long-term stability, without making it contain. In addition, it becomes possible to improve stability further if a specific container is used as a container with which the liquid pharmaceutical preparation of this invention is filled so that it may mention later.
- the pH of the liquid pharmaceutical preparation of the present invention can be adjusted by a method known per se, for example, using a buffer and a pH adjuster.
- liquid pharmaceutical preparation of the present invention can be produced by various production methods known per se.
- the various components described above constituting the liquid pharmaceutical preparation of the present invention may be appropriately selected, mixed with an appropriate solvent and dissolved.
- the liquid pharmaceutical preparation of the present invention is produced as a liquid pharmaceutical preparation for subcutaneous administration, a liquid pharmaceutical preparation for injection, or a liquid pharmaceutical preparation for injection for subcutaneous administration, it is preferable to use an aqueous liquid pharmaceutical preparation.
- an aqueous liquid pharmaceutical preparation it is preferable that the preparation be sterilized before administration.
- the aseptic process is adopted as the aseptic process, each weighed raw material is dissolved in water for injection and the like, and the solution can be filter-sterilized to produce a liquid pharmaceutical preparation.
- Water for injection is generally understood as sterile purified water adapted to the pyrogen (endotoxin) test, and water for injection manufactured by the distillation method may also be referred to as distilled water for injection.
- the liquid pharmaceutical preparation for injection is further filled and sealed in a container that has been subjected to washing and sterilization treatment, and after inspection, packaging, etc., an injection prepared by filling the liquid pharmaceutical preparation for injection can be produced.
- a container for example, an ampoule, a vial, a prefilled syringe, a bag and the like can be exemplified.
- the material of the container is not particularly limited, and glass and plastic can be mentioned. From the viewpoint of strength, ease of handling, safety, etc., plastic can be preferably exemplified as the material of the container.
- the liquid pharmaceutical preparation of the present invention may include an aspect of a liquid pharmaceutical preparation reconstituted from a lyophilised preparation. Also, the liquid pharmaceutical preparation of the present invention may not be a liquid pharmaceutical preparation that is reconstituted from a lyophilised preparation. Conventionally, it is known that a lyophilized preparation containing teriparatide or a salt thereof is dissolved in physiological saline or the like at the time of use to make a liquid pharmaceutical preparation, but the liquid pharmaceutical preparation of the present invention is such a lyophilized preparation Or a preparation (pre-liquidized preparation) which does not undergo such a lyophilized preparation.
- Deamidation means a reaction in which the amide in the organic compound of interest is removed nonenzymatically. Although some proteins and peptides (hereinafter sometimes referred to as proteins etc.) contain asparagine residues and glutamine residues, all residues have an amide in the side chain, and this amide is The reaction to be removed is also included in the deamidation (Non-patent Document 6). Degradation of proteins and the like in pharmaceutical preparations such as proteins and the subsequent reduction in activity can present important challenges in the pharmaceutical industry.
- Proteins etc. differ in their primary to quaternary structures. And, it is also known that the deamidation reaction depends on the primary to quaternary structures of individual proteins to be targeted (Non-patent Document 6).
- Non-Patent Document 8 the deamidation reaction of asparagine residues of small peptides is not affected by the ionic strength of the reaction solution (Abstract), and addition of sodium chloride to the reaction solution does not suppress the deamidation reaction (Table III) is disclosed. Further, in the literature to which Non-Patent Document 8 refers, it is also reported that the increase in ionic strength by the addition of sodium chloride accelerates the deamidation reaction (McKerrow and Robinson, 1971; Scotchler and Robinson, 1974; page 22553, left column) ).
- the deamidation reaction of teriparatide acetate in the liquid pharmaceutical preparation is significantly suppressed by adding one or more inorganic salts such as sodium chloride and / or an organic salt (component 2) to the liquid pharmaceutical preparation. It can be done.
- Deamidation of teriparatide or a salt thereof includes any biochemical deamidation reaction exhibited by teriparatide or a salt thereof.
- deamidation refers to an amide functional group in the side chain of at least one residue of asparagine residues at positions 10, 16, and 33 and glutamine residue at position 29 in the amino acid sequence of teriparatide or a salt thereof. Can be the reaction to be removed.
- teriparatide there are lysine, serine and phenylalanine as amino acid residues at the C-terminal side of asparagine residues.
- the deamidation in the side chain of an asparagine residue is caused by the reaction of the nitrogen in the peptide bond formed with the asparagine residue and the adjacent residue, and the amide in the side chain of the asparagine residue via a succinimide intermediate. It means a reaction that changes to an aspartic acid residue or an isoaspartic acid residue.
- Deamidation in the side chain of glutamine residues is also similar to deamidation in the side chain of asparagine residues.
- the deamidation reaction in which the 16th asparagine residue from the N terminus of the component 1 changes to an aspartate residue, the 16th asparagine residue from the N terminus of the component 1 is an isoasparginate residue The deamidation reaction which changes into can be preferably illustrated.
- Deamidation suppression of teriparatide or a salt thereof can be detected and quantified using known techniques by, for example, LC / MS / MS (liquid chromatography / tandem mass spectrometry).
- the mass ratio of Component 1 to Component 2 suitable for suppressing the deamidation of Component 1 is not particularly limited, but as described above, the lower limit is preferably, for example, 1: 5 or more, 1:10 or more, 1: More preferably, it is 15 or more, more preferably 1:20 or more, and most preferably 1:35 or more.
- the upper limit is, for example, preferably 1: 500 or less, more preferably 1: 300 or less, and most preferably 1:80 or less.
- component 2 can be added to the liquid pharmaceutical preparation for the purpose of suppressing deamidation of component 1, it is also preferable to optimize the pH of the liquid pharmaceutical preparation.
- the above-mentioned suitable pH range can be exemplified as a suitable pH for suppressing the deamidation of Component 1. It is further preferred to add component 2 to the liquid pharmaceutical formulation and to optimize the pH.
- the pH is preferably 4.6 or less, more preferably 4.4 or less, or 4.1 or less.
- the lower limit is not particularly limited, but is preferably 3.0 or more, and more preferably 3.4 or 3.6 or more.
- the pH is preferably 4.6 or less, more preferably 4.4 or less, or 4.1 or less.
- the lower limit is not particularly limited, but is preferably 3.0 or more, and more preferably 3.4 or 3.6 or more.
- a buffer may or may not be substantially contained in the liquid pharmaceutical preparation for the purpose of suppressing deamidation of Component 1.
- the component 2 when the component 2 is added to the liquid pharmaceutical preparation, it is preferable to further contain a buffer.
- the pH of the liquid pharmaceutical preparation is less than 5.0, it is preferable to add the component 2 to the liquid pharmaceutical preparation and to substantially contain a buffer.
- the pH of the liquid pharmaceutical preparation may be less than 5.0, and while the component 2 is added to the liquid pharmaceutical preparation, the liquid pharmaceutical preparation may be substantially free of a buffer.
- the specificity of the reaction attributed to component 2 eg, suppressing the influence on the isomerization reaction in which the 30th aspartic acid residue from the N terminus of component 1 is changed to an isoaspartic acid residue
- the liquid pharmaceutical preparation may be substantially free of a buffer.
- the specificity of the reaction attributed to Component 2 can be improved.
- the specificity of the reaction for example, the specificity such as suppressing the deamidation reaction of the component 1 can be mentioned while suppressing the influence of the component 1 on the isomerization reaction.
- the specificity which suppresses the deamidation reaction in which the 16th asparagine residue from the N-terminus of is converted to isoasparginate can also be preferably exemplified.
- the method is particularly advantageous for storing the liquid pharmaceutical preparation according to the invention, in particular for the purpose of maintaining its quality when stored at room temperature or under refrigeration, for a period of three months or more. And so on.
- Isomerization of the aspartic acid residue of teriparatide or a salt thereof is a reaction in which the 30th aspartic acid residue from the N-terminus is changed to an isoaspartic acid residue in the amino acid sequence of teriparatide or a salt thereof be able to.
- the structural change from an aspartic acid residue to an isoaspartic acid residue can be understood by those skilled in the art (such as non-patent document 8), and the reaction can be detected and quantified using known techniques.
- the mass ratio of Component 1 to Component 2 suitable for suppressing isomerization of the aspartic acid residue of Component 1 (hereinafter referred to as the ratio of (Component 1) :( Component 2) as appropriate, is not particularly limited, As described above, the lower limit is, for example, preferably 1: 5 or more, more preferably 1:10 or more, 1:15 or more, and even more preferably 1:20 or more, and more preferably 1:35 or more. It is most preferable that On the other hand, the upper limit is, for example, preferably 1: 500 or less, more preferably 1: 300 or less, and most preferably 1:80 or less. When the component 2 of 1:20 or more is contained in the liquid pharmaceutical preparation, the isomerization reaction of the aspartic acid residue of the component 1 can be significantly suppressed.
- component 2 can be added to the liquid pharmaceutical preparation for the purpose of suppressing isomerization of the aspartic acid residue of component 1, it is also preferable to optimize the pH of the liquid pharmaceutical preparation.
- the above-mentioned suitable pH range can be exemplified as a suitable pH for suppressing the isomerization of the aspartic acid residue of Component 1. It is further preferred to add component 2 to the liquid pharmaceutical formulation and to optimize the pH.
- the pH is preferably 4.6 or less, more preferably 4.4 or less, or 4.1 or less.
- the lower limit is not particularly limited, but is preferably 3.0 or more, and more preferably 3.4 or 3.6 or more.
- the isomerization of aspartic acid residues can be significantly suppressed even without the addition of Component 2 to the liquid pharmaceutical preparation.
- a buffer may or may not be substantially contained in the liquid pharmaceutical preparation for the purpose of suppressing isomerization of the aspartic acid residue of Component 1.
- the component 2 when the component 2 is added to the liquid pharmaceutical preparation, it is preferable to further contain a buffer.
- the pH of the liquid pharmaceutical preparation is less than 5.0
- the purpose is to suppress the isomerization reaction in which the 30th aspartic acid residue from the N-terminus of Component 1 is changed to an isoaspartic acid residue
- the pH is less than 5.0
- the method is particularly advantageous for storing the liquid pharmaceutical preparation according to the invention, in particular for the purpose of maintaining its quality when stored at room temperature or under refrigeration, for a period of three months or more. And so on.
- PTH is an aqueous solution agent
- its storage stability is poor, and it is important to avoid this problem (Patent Document 2).
- Patent Document 2 the degradation of proteins and the like in pharmaceutical preparations such as proteins and the subsequent reduction in activity can present important challenges in the pharmaceutical industry.
- analogues of Component 1 generated or increased in the process of storing the liquid pharmaceutical preparation.
- analogues of Component 1 such as deamidated form of Component 1, cleaved form of Component 1, isomeric form of aspartic acid residue of Component 1, oxidized form of Component 1 etc. It is preferable to suppress the occurrence or increase of Therefore, for the purpose of enhancing the storage stability of the liquid pharmaceutical preparation of the present invention, it is preferable to take measures such as addition of at least one of the components 2 to 5, pH optimization, and storage temperature / humidity control.
- the pH can be neutral or acidic (pH is 8.0 or less), and the lower limit is, for example, 3.0 or more, 3.6 or more, 3.8 or more, 4.0 or more, or 4. More than 0, 4.1 or more, 4.2 or more, or 4.4 or more is preferable.
- the upper limit may be, for example, 7.0 or less, less than 7.0, 6.0 or less, 5.0 or less, less than 5.0, 4.9 or less, 4.8 or less, or 4.6 or less preferable. As a suitable range, it can be 3.0 or more and 5.0 or less, or 4.0 or more and 5.0 or less, for example.
- the container for storing the liquid pharmaceutical preparation during storage is not particularly limited, but glass medical containers (glass ampoules, glass vials, glass syringes, etc.) and plastic medical containers (plastic ampoules, plastic vials, plastic Preferably, it is filled in a syringe or the like) and stored.
- a buffer may or may not be substantially contained in the liquid pharmaceutical preparation.
- the buffer is not substantially contained in the liquid pharmaceutical preparation.
- the buffer be substantially contained in the liquid pharmaceutical preparation.
- the pH of the liquid pharmaceutical preparation of the present invention at the start of storage is preferably 4.0 or more and 5.0 or less.
- the liquid pharmaceutical preparation of the present invention For the purpose of enhancing the storage stability of the liquid pharmaceutical preparation of the present invention, it is preferable to add at least one of the components 2-5 to the preparation, and at least component 5 is contained in the liquid pharmaceutical preparation of the present invention. Is preferred.
- the pH at the start of storage of the liquid pharmaceutical preparation of the present invention is not particularly limited, but for example, preferably 4.0 or more and 5.2 or less.
- component 5 is contained in the liquid pharmaceutical preparation of the present invention, it is preferable to substantially contain the buffer of the liquid pharmaceutical preparation of the present invention, and more preferable to substantially contain the acetate buffer.
- the addition amount of the component 5 is not particularly limited, but the weight ratio of the component 1: component 5 is preferably 1: 1 to 2,000.
- Component 1 content and Component 1 related substance total amount can be mentioned, and Component 1 content after storage for a certain period of time (e.g.
- the storage stability of the liquid pharmaceutical preparation of the present invention can be evaluated by measuring / quantifying the total amount of component 1 analogues or the like, which may be relative to the content).
- the total amount of teriparatide or a salt thereof (component 1) in the liquid pharmaceutical preparation of the present invention and the amount of component 1 are detected and known using, for example, known techniques by LC / MS / MS (liquid chromatography / tandem mass spectrometry) It can be quantified.
- Method of suppressing the formation of the oxidant of Component 1 It is also known that addition of methionine to teriparatide aqueous solution stabilizes teriparatide, and that teriparatide aqueous solution filled in a radiation-sterilized resin-made prefilled syringe is stabilized by methionine contained in the same solution (patent documents 2 to 6). 3).
- the oxidized form of component 1 means an oxidized form of at least one or more of various types of oxidized component 1 For example, preferred are 8 oxidants, 18 oxidants, 8-18 oxidants, and 23 oxidants.
- the term “8-oxidant” refers to an oxidized form of teriparatide or a salt thereof (component 1) in which the methionine residue at the eighth position from the N-terminus is sulfoxidated
- the term “18-oxidant” refers to the 18th And the 8-18 oxidized form mean the oxidized form in which the 8th and 18th methionine residues from the N terminus of the component 1 are both sulfoxided, respectively.
- 23-oxidant means an oxidized form in which the 23rd tryptophan residue from the N-terminus of teriparatide or a salt thereof (component 1) is oxidized.
- any of the analogues 9 'to 11' described in Patent Document 5 can be preferably exemplified.
- the analogue 9 'described in Patent Document 5 is a teriparatide analog (human) in which the residue corresponding to tryptophan 23 of teriparatide is the following (a) residue and the other structure is identical to that of the original teriparatide (human PTH (1-34) -Trp23 [dioxide]).
- the related substance 10 ' is a residue corresponding to tryptophan 23 of teriparatide is a residue shown by the following (c) -1 or (c) -2 below, and the other structure is identical to the original teriparatide Indicates teriparatide analogue (human PTH (1-34) -Trp23 [mono-oxidation]).
- the analogue 11 ' is a teriparatide analog (human PTH (1-34)-) whose residue corresponding to tryptophan 23 in teriparatide is the following residue (b) and the other structure is identical to that of the original teriparatide: Trp23 [dioxide-formic acid elimination] is meant.
- the suppression of the formation of the oxidized form of Component 1 in the liquid pharmaceutical preparation of the present invention may be, for example, the suppression of the formation of the oxidized form of Component 1 in the preparation at the time of production of the liquid pharmaceutical preparation of the present invention. It may be suppression of the formation of the oxidized form of component 1 in the preparation during transport / storage of the pharmaceutical preparation.
- methionine component 3
- / or mannitol component 4
- component 3 is used as a preparation in order to suppress the formation of at least one or more of the 8 oxidized form, 18 oxidized form and 8-18 oxidized form. It is preferable to contain it.
- the content of the component 3 is not particularly limited, it is preferable that the mass ratio of the component 1: component 3 is 1: 0.5 or more.
- the upper limit of the addition amount of the component 3 is not particularly limited, it is preferably 100 times or less, 50 times or less, 10 times or less, or 5 times or less of the component 1 and is preferably 1 time or less. That is, it is preferable to incorporate Component 1 and Component 3 in the liquid pharmaceutical preparation so that the mass ratio of Component 1: Component 3 is 1: 0.2 to 1.0.
- the pH can be neutral or acidic (pH is 8.0 or less), and the lower limit is, for example, 3.0 or more, 3.6 or more, 3.8 or more, 4.0 or more, or 4. More than 0, 4.1 or more, 4.2 or more, or 4.4 or more is preferable.
- the upper limit may be, for example, 7.0 or less, less than 7.0, 6.0 or less, 5.0 or less, less than 5.0, 4.9 or less, 4.8 or less, or 4.6 or less preferable.
- a buffer may or may not be substantially contained in the preparation for enhancing the suppression of the formation of the oxidized form of component 1 in the liquid pharmaceutical preparation of the present invention. In order to enhance the suppression of the formation of the oxidized form of component 1 in the liquid pharmaceutical preparation of the present invention, it is preferred that the buffer be substantially not contained.
- the amount of oxidized form of teriparatide or a salt thereof (component 1) is detected and known using, for example, a known technique by LC / MS / MS (liquid chromatography / tandem mass spectrometry) It can be quantified.
- the method is particularly advantageous for storing the liquid pharmaceutical preparation according to the invention, in particular for the purpose of maintaining its quality when stored at room temperature or under refrigeration, for a period of three months or more. And so on.
- a test of a liquid pharmaceutical preparation containing component 1 comprising the step of detecting or quantifying the presence of the following analogues (1) to (4) and at least any one of them:
- a method e.g. a quality inspection method
- a deamidated form (N16 ⁇ iso-D16) is a deamidated form in which the asparagine residue present 16th from the N-terminus of teriparatide is changed to an isoaspartic acid residue, and the other residues correspond to teriparatide Deamidate, which is identical to the residue.
- a deamidated form (N16 ⁇ D16) is a deamidated form in which an asparagine residue present 16th from the N-terminus of teriparatide is changed to an aspartic acid residue, and the other residues are the corresponding residues of teriparatide Means a deamidated form which is identical to
- Asp isomer (D30 ⁇ iso-D30) is an isomer in which the aspartic acid residue located 30th from the N-terminus of teriparatide is changed to an isoaspartic acid residue, and the other residues are teriparatide Means an isomer which is identical to the corresponding residue of
- the deamidated form (N10) -Asp isomerized form (D30 ⁇ iso-D30) is a deamidated form produced by deamidating an asparagine residue present 10th from the N-terminus of teriparatide, As a result, it is a deamidated form in which the same residue is changed to an aspartic acid residue or an isoaspartic acid residue, and an aspartic acid residue present 30th from the N terminus of teriparatide is an isoaspartic acid residue It refers to an aspartic acid residue isomerization product that changes.
- Analogs can be detected or quantified using well known techniques, for example by LC / MS / MS (liquid chromatography / tandem mass spectrometry). The methods and analogs are useful, for example, to control the quality of liquid pharmaceutical formulations containing ingredient 1.
- a liquid pharmaceutical preparation comprising component 1 in which the content of at least one of the above-mentioned analogues (1) to (4) is reduced.
- the content of each analog is not particularly limited, but is 5% or less, 4% or less, 3% or less, or 2% or less as a percentage (%) based on 100% of the total mass of teriparatide and its analogues Is preferably, and more preferably 1% or less.
- Light stabilization method It is preferable that at least several thousands items of medical pharmaceuticals requiring shading storage exist and are stored under sufficiently light stable conditions for proper management of pharmaceutical preparations.
- Non-patent Document 12 a PTH aqueous solution stable to light and heat is disclosed.
- the light stability of the liquid pharmaceutical preparation of the present invention can be improved by shielding it from light, for example, by storing it in a box-packed state.
- the material, structure, and shape of the box used for packaging are not particularly limited, but the box may be a pharmaceutical individual box collectively packaging one or more liquid pharmaceutical preparations, and one or more pharmaceutical individual packaging It may be an original cardboard box for packaging a box.
- the pharmaceutical packaging case can be a paper box that prevents damage to the pharmaceutical preparation, contamination of foreign matter, and the like, and that includes the package insert. Preferably, perforations, zippers and the like are provided in the unsealing portion.
- the paper quality of the pharmaceutical packaging box may be cardboard or may be paper.
- the liquid pharmaceutical preparation may be blister-packed or pillow-packaged as part of a measure against damage to the medicine or contamination of foreign matter, and then packaged in a medicine packaging box.
- the material of the blister package and the pillow package is not particularly limited, but examples thereof include plastic materials.
- the material, structure, shape, etc. of the original cardboard are not particularly limited, but may be, for example, A flute (A / F), B flute (B / F), or double flute (AB / F).
- the surface liner can be, for example, C5, K5, K6 or K7 and the core can be S120 or S160.
- a reinforced core (such as P160) may be used instead of the core.
- the surface liner may be single-sided (single-sided cardboard) or double-sided (double-sided cardboard).
- a flute (K6xS120xK6) can be illustrated preferably.
- the liquid pharmaceutical preparation preferably contains methionine, and further preferably contains sodium chloride or mannitol.
- the photostability can be measured using, as an indicator, the amount of the analogue of Component 1 contained after storage of the liquid pharmaceutical preparation, in particular, the amount of 8-oxidant and / or 18-oxidant. That is, the degree of light stabilization can be measured by using the suppression of generation of these oxidants as an index.
- the liquid pharmaceutical preparation is preferably a preparation filled in a plastic or glass vial or a prefilled syringe.
- Example 1 Preparation of a Liquid Pharmaceutical Preparation: (1) Preparation of a liquid pharmaceutical preparation subjected to a test for suppressing the formation of a deamidated form and an aspartic acid residue isomerized form: (1-1) Production 1: Formulations 1 to 11 were prepared according to Table 1 below.
- each additive solution described in the “Additive” column in the table is mixed with water for injection, 1 mL of teriparatide acetate solution (2820 ⁇ g / mL as teriparatide) is added to the mixture, and about 19 mL of drug solution a is added Prepared. Furthermore, the pH adjustment agent described in the "pH adjustment agent” column in the table is added to the chemical solution a to adjust to the pH described in the "pH” column in the table, and each formulation of 20 mL is prepared. Prepared.
- each formulation was filter-sterilized and then 0.2 mL each was filled in a plastic syringe to produce a plastic syringe (prescription formulation) filled with each formulation, which was then subjected to a deamidation product formation inhibition test.
- composition of each formulation is as described in the "final content” column in the table.
- Control formulation 12 to control formulation 17 were prepared according to Table 2 below.
- each formulation is as follows. First, a solution containing each additive solution described in the "additive" column in the table and a solution obtained by dissolving a solution of teriparatide acetate (28.2 mg as teriparatide) were mixed to prepare a total of 175 mL of a chemical solution a. Thereafter, the pH adjuster described in the "pH adjuster" column in the table is added to the chemical solution a to adjust to the pH described in the "pH” column in the table, and each formulation of 200 mL in total is prepared. did.
- each formulation was filter-sterilized and then 0.2 mL each was filled in a plastic syringe to produce a plastic syringe (prescription formulation) filled with each formulation, which was then subjected to a deamidation product formation inhibition test.
- composition of each formulation is as described in the "final content” column in the table.
- each additive solution / additive described in the “Additive” column in the table is mixed with water for injection, 1 mL of teriparatide acetate solution (2820 ⁇ g / mL as teriparatide) is added to the mixture, and approximately 19 mL of A drug solution a was prepared. Furthermore, the pH adjustment agent described in the "pH adjustment agent” column in the table is added to the chemical solution a to adjust to the pH described in the "pH” column in the table, and each formulation of 20 mL is prepared. Prepared.
- each formulation was filter-sterilized and then 0.2 mL each was filled in a plastic syringe to produce a plastic syringe (prescription formulation) filled with each formulation, which was then subjected to a deamidation product formation inhibition test.
- composition of each formulation is as described in the "final content” column in the table.
- Formulations 30-32 were prepared according to Table 4 below.
- each formulation is as follows. First, each additive described in the "additive" column in the table and teriparatide acetate (141 mg as teriparatide) were mixed with water for injection, and after dissolution was confirmed, a total amount of 980 g of drug solution a was prepared using water for injection. Thereafter, hydrochloric acid was added to the drug solution a to adjust to the pH described in the “pH” column in the table, and then a formulation of 1000 g in total was prepared using water for injection.
- each formulation was filter-sterilized and then 0.2 mL each was filled in a plastic syringe to produce a plastic syringe (prescription formulation) filled with each formulation, which was subjected to a methionine effect test.
- composition of each formulation is as described in the "final content” column in the table.
- Formulations 33-40 were prepared according to Table 5 below.
- each additive described in the "additive" column in the table was mixed with water for injection to prepare a total of 3000 mL of solution a.
- Teriparatide acetate (282 mg as teriparatide) was dissolved in 1600 mL of the solution a to prepare a drug solution a.
- a drug solution a was prepared using said solution a.
- composition of each formulation is as described in the "final content” column in the table.
- Formulations 41 and 42 were prepared according to Table 6 below.
- each additive solution / additive described in the “Additive” column in the table is mixed with water for injection, and a solution containing teriparatide acetate described in the “Teriparatide added amount” column in the table is added to the mixed liquid Was added to prepare about 19 mL of a drug solution a. Since the pH of the drug solution a was the pH described in the “pH” column in the table, the pH adjustment with a pH adjuster was not performed, and further, the solution solution a was subjected to a dose-up and 20 mL of each formulation Prepared.
- each formulation was filter-sterilized and then 0.2 mL each was filled in a plastic syringe to produce a plastic syringe (formulation formulation) filled with each formulation, which was subjected to a stability test for control comparison.
- each additive solution / additive described in the “Additive” column in the table is mixed with water for injection, 1 mL of teriparatide acetate solution (2820 ⁇ g / mL as teriparatide) is added to the mixture, and approximately 19 mL of A drug solution a was prepared. Furthermore, the pH adjustment agent described in the "pH adjustment agent” column in the table is added to the chemical solution a to adjust to the pH described in the "pH” column in the table, and each formulation of 20 mL is prepared. Prepared.
- the formulation filled with each formulation was manufactured by filling each in 0.4 mL glass vials, and the formulation was subjected to a stability test for additive evaluation.
- composition of each formulation is as described in the "final content” column in the table.
- pH adjustment with the pH adjuster was not performed, and only the measurement was performed to adjust to the pH described in the “pH” column. .
- the formulation 60 and the formulation 61 were prepared according to Table 8 below.
- the specific preparation method of each formulation is as follows. After weighing the teriparatide amount described in the "Additive” column in the table, dissolve with the solvent described in the “Solvent” column in the table, and measure up to the volume described in the "Mess up” column in the table. The formulation was prepared.
- each formulation was filter-sterilized and then filled with 0.4 mL each in a glass vial to produce a formulation filled with each formulation, which was then subjected to a stability test for additive evaluation.
- each additive described in the "additive" column in the table was mixed with water for injection to prepare a total of 3000 g of solution a.
- the formulation 62 was prepared by dissolving teriparatide acetate (352.5 mg as teriparatide) in 2480 g of solution a, and using solution a to make the total amount 2500 g.
- formulation 62 was filter-sterilized, 0.2 mL each was filled in a plastic syringe, and the syringe filled with the formulation 62 was used as a formulation 62 formulation.
- Example 2 (Test for suppressing formation of deamidated form and aspartic acid residue isomerized form): (1) Test method: Production of deamidated and aspartic acid isomer isomer using Formulation 1 to 29 prepared in the above-mentioned "Liquid pharmaceutical preparation subjected to the test for suppressing formation of deamidated compound and aspartic acid residue isomer" A suppression test was performed.
- Test results The test results are described in Tables 10-14 below. The numerical values in the table indicate the percentage (%) when the total amount of teriparatide and its related substances contained in the formulation is 100.
- the “deamidated form (N16 ⁇ iso-D16)” in the table is a deamidated form produced by deamidating an asparagine residue present 16th from the N-terminus of teriparatide, as a result, A deamidated form in which the residue is changed to an isoaspartic acid residue is meant.
- the “deamidated form (N16 ⁇ D16)” in the table is a deamidated form produced by deamidating an asparagine residue present 16th from the N-terminus of teriparatide, and as a result, the same residue Means a deamidated form converted to an aspartic acid residue.
- Asp isomerate (D30 ⁇ iso-D30)” in the table means aspartate isomerization in which the aspartic acid residue present 30 from the N-terminus of teriparatide is changed to an isoaspartic acid residue Means the body.
- deamidated form (N10) -Asp isomerized form (D30 ⁇ iso-D30) is formed by deamidating an asparagine residue present 10th from the N-terminus of teriparatide
- a deamidated form which is a deamidated form in which the same residue is changed to an aspartic acid residue or an isoaspartic acid residue, and an aspartic acid residue present 30th from the N-terminus of teriparatide It means an aspartic acid residue isomerized form in which a group is changed to an isoaspartic acid residue.
- deamidated form means deamidated form (N10) —Asp isomerized form (D30 ⁇ iso-D30), deamidated form (N16 ⁇ iso-D16), and deamidated form (N16 ⁇ D16) (Namely, the numerical value in the table of the deamidated form means the total of the three compounds).
- Asp isomerate in the table means a generic name of deamidated form (N10) -Asp isomerate (D30 ⁇ iso-D30) and Asp isomerate (D30 ⁇ iso-D30) (ie, The numerical value in the table of the Asp isomerized form means the total amount of the above two compounds).
- Example 3 effect test of methionine: (1) Test method: The methionine effect test was conducted using the formulations 30 to 32 prepared in the above-mentioned “Liquid pharmaceutical preparation subjected to methionine effect test”.
- each formulation was stored in a stability tester at 5 ° C., and then sampling was performed at 6 months, and the stability was measured by high performance liquid chromatography.
- Test results The test results are described in Tables 15 and 16 below.
- the “analog mass” in the table indicates the percentage (%) when the total amount of teriparatide and its analogue contained in the formulation is 100.
- the content at the beginning of the table indicates the percentage (%) of the amount of teriparatide remaining in the sixth month when the amount of teriparatide before storage is 100.
- the "8 oxidized form” in the table refers to teriparatide oxidized form in which the methionine residue from the N-terminus to the 8th of teriparatide is sulfoxided
- the "18 oxidized form” in the table refers to the 18th
- Example 4 Stability Test on a Filled Container (1) Test method: Formulation 33-40 ampoule formulation prepared in the above-mentioned "Liquid pharmaceutical preparation subjected to stability test on filled container", and formulation prepared in the above "liquid pharmaceutical preparation subjected to stability test on filled container” Stability studies were performed using a 33-40 syringe formulation.
- each formulation was stored in a stability tester at 25 ° C./60% RH, then sampling was performed at three months, and the stability was measured by high performance liquid chromatography.
- Test results The test results are described in Tables 17 and 18 below.
- the “content to start with” in the table indicates the percentage (%) of the amount of teriparatide remaining in the third month when the amount of teriparatide before storage is 100.
- the “total amount of related substances” in the table means the percentage (%) of the total amount of related substances present in the third month, assuming that the existing in the third month (the amount of teriparatide and the total amount of the related substances) is 100. Show.
- Example 5 (stability test for control comparison): (1) Test method: Formulations 41 to 42 prepared in the above-mentioned “Liquid pharmaceutical preparation subjected to stability test for control comparison” and the formulations prepared in the above “Liquid pharmaceutical preparation subjected to stability test on filled container” 38 Stability studies were performed using a syringe formulation.
- each formulation was stored in a stability tester at 25 ° C./60% RH, then sampling was performed at 1 and 3 months, and the stability was measured by high performance liquid chromatography.
- Test results The test results are described in Table 19 below. "Content to start (after 3 months storage)” in the table indicates the percentage (%) of the amount of teriparatide remaining in the third month when the amount of teriparatide before storage is 100.
- the “total amount of related substances (after 3 months storage)” in the table means the total amount of related substances present in the third month when the amount of teriparatide and the total amount of related substances present in the third month is 100. Indicates the percentage (%) of
- Example 6 Stability test for specific analogue suppression: (1) Test method: Using formulations 33 and 38 prepared in “Preparation of liquid pharmaceutical formulation subjected to stability test on filled container” described above, and formulation 62 prepared in “Preparation of control liquid pharmaceutical formulation” described above Stability studies on specific analog suppression were performed.
- Detector Ultraviolet absorptiometer (measurement wavelength: 214 nm)
- Column A stainless steel tube with an inner diameter of 4.6 mm and a length of 150 mm is packed with 3.5 ⁇ m octadecylsilylated silica gel for liquid chromatography (Agilent Tech Zorbax 300SB-C18 manufactured by nologies, or equivalent) (3)
- Column temperature Constant temperature around 40 ° C.
- Mobile phase Mobile phase
- Mobile phase A Dissolve 28.4 g of anhydrous sodium sulfate in 900 mL of water, adjust to pH 2.3 with phosphoric acid and then add water. Make up to 1000 mL.
- Mobile phase B Dissolve 28.4 g of anhydrous sodium sulfate in 900 mL of water, adjust to pH 2.3 with phosphoric acid, and add water to make 1000 mL. Add 500 mL of acetonitrile to 500 mL of this solution.
- Transfer of Mobile Phase The concentration ratio is controlled by changing the mixing ratio of mobile phase A and mobile phase B as shown in Table 20 below. (6) Flow rate: 1.0 mL per minute (7) Detection time: 45 minutes after injection of the sample solution. However, it is from behind the solvent peak.
- Test results The amounts of related substances with a relative retention time of 0.72 for each formulation are shown in Table 21 below.
- the “starting content” in the table indicates the proportion (%) of the relative substance mass having a relative retention time of 0.72 that was present when the amount before storage (the amount of teriparatide and the total amount of related substances) was 100.
- the “3 months content” in the table means the relative substance with a relative retention time of 0.72 existing in the 3rd month, assuming that the 3rd month (the amount of teriparatide and the total amount of related substances) is 100. Indicates the percentage (%) of the amount.
- the analogue 9 'described in Patent Document 5 is a teriparatide analog (human) in which the residue corresponding to tryptophan 23 of teriparatide is the above-mentioned (a) residue and the other structure is identical to that of the original teriparatide (human PTH (1-34) -Trp23 [dioxide]) is meant.
- the related substance 10 ' is a residue corresponding to tryptophan 23 of teriparatide is the residue shown in (c) -1 or (c) -2 above, and the other structure is identical to the original teriparatide Indicates teriparatide analogue (human PTH (1-34) -Trp23 [mono-oxidation]).
- the analogue 11 is a teriparatide analog (human PTH (1-34)-) whose residue corresponding to tryptophan 23 in teriparatide is the above residue (b) and the other structure is identical to that of the original teriparatide Trp23 [dioxide-formic acid elimination] is meant.
- Example 7 (stability test for additive evaluation): (1) Test method: A stability test for additive evaluation was conducted using formulations 43 to 61 prepared in the "Preparation of liquid pharmaceutical preparation subjected to stability test for additive evaluation" described above.
- Test results The test results are shown in Table 22 below. In the table, "-" means the fact that it was not measured.
- the “starting content” in the table indicates the percentage (%) of the total amount of related substances that were present when the amount of teriparatide and the total amount of related substances before storage was 100.
- the “one month content” in the table means the percentage (%) of the total amount of related substances present in the first month when the amount of teriparatide and the total amount of related substances present in the first month is 100.
- the “3 months content” in the table means the percentage (%) of the total amount of related substances present in the third month, assuming that the present (the amount of teriparatide and the total amount of related substances) present in the third month is 100. Show.
- Example 8 (light stability test): (1) Test method: Formulation 38 Syringe preparation prepared in the above-mentioned “Liquid pharmaceutical preparation subjected to stability test for filled containers” or the same preparation packaged in a paper box or the like is used for a commercial light stability test device, and D65 lamp is used as a light source (Illuminance: 2500 lx), 20 days as a period satisfying 1.2 million lx ⁇ hr and 200 w ⁇ h / m 2 under conditions of 5 ° C. ⁇ 3 ° C., or 10 days as a period satisfying 600,000 lx ⁇ hr It was exposed to light.
- Test method Formulation 38 Syringe preparation prepared in the above-mentioned “Liquid pharmaceutical preparation subjected to stability test for filled containers” or the same preparation packaged in a paper box or the like is used for a commercial light stability test device, and D65 lamp is used as a light source (Illuminance: 2500 lx), 20 days as a period
- the same preparation packaged in a paper box or the like refers to a syringe preparation incorporated in a device, which is further blister-packaged and enclosed in a separate box.
- Test results The measurement results are shown in the following table. Each numerical value in the measurement time column indicates the ratio (%) of the corresponding oxidized form amount when the value before storage (the amount of teriparatide and the total amount of related substances) is 100.
- the liquid pharmaceutical preparation of the present invention is excellent in terms of physical properties and pharmacokinetics.
- Each method (deamidation reaction suppression method, storage method, and analog formation suppression method) of the present invention is also a revolutionary key drug control method.
- the present invention is very useful in the pharmaceutical industry.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Endocrinology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Diabetes (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Dermatology (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
本発明の液状医薬製剤の一態様は、少なくとも1種の無機塩及び/又は有機塩を含有する。さらに、本発明の液状医薬製剤の一態様は、そのpHが所定範囲(例:3.0~5.0)にある。このような液状医薬製剤では、テリパラチド又はその塩の脱アミド体の生成が抑制され得る。
本発明の液状医薬製剤の一態様は、少なくとも1種の無機塩及び/又は有機塩を含有する。また、本発明の液状医薬製剤の一態様は、そのpHが所定範囲(例:3.0~5.0)にある。このような液状医薬製剤では、テリパラチド又はその塩のアスパラギン酸残基異性化体の生成が抑制され得る。
本発明の液状医薬製剤の一態様は、そのpHが所定範囲(例:4.0~5.0)にある。より具体的な態様は、ガラス製医療用容器に充填され、緩衝剤を実質的に含有せず、そのpHが所定範囲(例:4.0~5.0)にある製剤である。また、より具体的な態様は、プラスチック製医療用容器に充填され、緩衝剤を実質的に含有し、さらに、D-マンニトールを含有し、そのpHが所定範囲(例:4.0~5.0)にある。また、本発明の液状医薬製剤の一態様は、特定の添加剤(例:α-シクロデキストリン)を含有する。このような液状医薬製剤は、長期に安定であり得る。
本発明の液状医薬製剤の一態様は、所定量のメチオニン(例:テリパラチド又はその塩とメチオニンの質量比が、1:0.5~1.0)を含有する。このような液状医薬製剤では、テリパラチド又はその塩の酸化体生成(例:テリパラチド又はその塩のN末端から8番目のメチオニン残基がスルホキシド化されたテリパラチド酸化体の生成)が抑制されている。本発明の液状医薬製剤の一態様は、マンニトールを含有する。このような液状医薬製剤では、テリパラチド又はその塩の酸化体生成(例:テリパラチド又はその塩における23位トリプトファン残基の酸化体の生成)が抑制され得る。
本発明の一態様は、特定のテリパラチド類縁体(例:脱アミド体、Asp異性化体)、同類縁体含有量が低減された高品質な液状医薬製剤、同類縁体の存在及び/又は存在量を指標とするテリパラチド又はその塩を含有する液状医薬製剤の検査方法である。
[1]
成分1及び成分2を含有する液状医薬製剤。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。
[2]
pHが5.0未満である、前記[1]に記載の液状医薬製剤。
[3]
成分1及び成分2を含有する液状医薬製剤であって、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有する液状医薬製剤(ただし、pHは5.0未満である。)。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。
[4]
成分1及び成分2を含有する液状医薬製剤であって、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有しない液状医薬製剤(ただし、pHは5.0未満である。)。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。
[5]
成分1及び成分2を含有する液状医薬製剤であって、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有しない液状医薬製剤(ただし、pHは5.0以上である。)。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。
[6]
成分1と成分2との質量比が1:20又は20以上である、前記[1]~[5]のいずれかに記載の液状医薬製剤。
[7]
成分1を含有する液状医薬製剤であって、pHが3.6~4.1である、液状医薬製剤。
・成分1)テリパラチド又はその塩。
[8]
成分1及び成分3を含有する液状医薬製剤であって、成分1と成分3との質量比が1:0.2~1.0である、液状医薬製剤。
・成分1)テリパラチド又はその塩。
・成分3)メチオニン。
[9]
成分1及び成分4を含有する、液状医薬製剤。
・成分1)テリパラチド又はその塩。
・成分4)D-マンニトール。
[10]
ガラス製医療用容器に充填されている、成分1を含有する液状医薬製剤であって、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含まず、かつ、pHが4.0を超え5.0以下である、液状医薬製剤;
・成分1)テリパラチド又はその塩。
[11]
プラスチック製医療用容器に充填されている、成分1を含有する液状医薬製剤であって、pHが4.0~4.2であり、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含み、さらに、成分4を含有する、液状医薬製剤;
・成分1)テリパラチド又はその塩。
・成分4)D-マンニトール。
[12]
成分1及び成分5を含有する液状医薬製剤。
・成分1)テリパラチド又はその塩。
・成分5)L-プロリン、ベタイン、エクトイン、ヒドロキシエクトイン、L-アルギニン塩酸塩、L-ヒスチジン、2-ヒドロキシプロピル-β-シクロデキストリン、α-シクロデキストリン、β-シクロデキストリン、γ-シクロデキストリン、N-アセチル-アルギニン、L-リジン塩酸塩、及び、N-アセチル-DL-トリプトファンからなる群より選ばれる1以上の成分。
[13]
成分5が、α-シクロデキストリン、β-シクロデキストリン、N-アセチル-アルギニン、L-プロリン、L-アルギニン塩酸塩、及び、L-リジン塩酸塩からなる群より選ばれる1以上の成分である、前記[12]に記載の液状医薬製剤。
[14]
成分2が、塩化ナトリウム、塩化カルシウム、塩化マグネシウム、臭化ナトリウム、酢酸ナトリウム、クエン酸三ナトリウム及び炭酸ナトリウムから選択される1種以上の塩である、前記[1]~[6]に記載の液状医薬製剤。
[15]
成分2が塩化ナトリウム及び/又はクエン酸三ナトリウムである、前記[14]に記載の液状医薬製剤。
[16]
pHが4.1以上4.6以下である、前記[3]又は[4]に記載の液状医薬製剤。
[17]
pHが5.0である、前記[5]に記載の液状医薬製剤。
[18]
成分1がテリパラチド酢酸塩である、前記[1]~[17]のいずれかに記載の液状医薬製剤。
[19]
成分1含有量がテリパラチド換算で25~30μgである、前記[1]~[18]のいずれかに記載の液状医薬製剤。
[20]
ヒト皮下投与用である、前記[1]~[19]のいずれかに記載の液状医薬製剤。
[21]
成分1を含む液状医薬製剤における成分1の脱アミド反応を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめることを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。
[22]
液状医薬製剤のpHが5.0未満である、前記[21]に記載の方法。
[23]
pH5.0未満の条件下、成分1を含む液状医薬製剤における成分1の脱アミド反応を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめると共に、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめることを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。
[24]
pH5.0未満の条件下、成分1を含む液状医薬製剤における成分1の脱アミド反応を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめると共に、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめないことを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。
[25]
pH5.0以上の条件下、成分1を含む液状医薬製剤における成分1の脱アミド反応を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめると共に、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめないことを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。
[26]
脱アミド反応の抑制が、成分1のN末端から16番目に位置する成分1におけるアスパラギン残基がイソアスパラギン酸残基に変化してなる成分1の脱アミド体の生成の抑制である、前記[25]に記載の方法。
[27]
成分2が、塩化ナトリウム、塩化カルシウム、塩化マグネシウム、臭化ナトリウム、酢酸ナトリウム、クエン酸三ナトリウム及び炭酸ナトリウムから選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)である、前記[21]~[26]のいずれかに記載の方法。
[28]
成分1を含む液状医薬製剤における成分1の脱アミド反応を抑制する方法であって、液状医薬製剤のpHを3.6~4.1とすることを手段とする方法;
・成分1)テリパラチド又はその塩。
[29]
成分1を含む液状医薬製剤における成分1のアスパラギン酸残基の異性化を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめることを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。
[30]
成分1を含む液状医薬製剤における成分1のアスパラギン酸残基の異性化を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめると共に、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめることを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。
[31]
アスパラギン酸残基の異性化の抑制が、成分1のN末端から30番目に位置するアスパラギン酸残基がイソアスパラギン酸残基に変化してなる成分1のアスパラギン酸残基の異性化の抑制である、前記[30]に記載の方法。
[32]
成分2が、塩化ナトリウム、塩化カルシウム、塩化マグネシウム、臭化ナトリウム、酢酸ナトリウム、クエン酸三ナトリウム及び炭酸ナトリウムから選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)である、前記[29]~[31]のいずれかに記載の方法。
[33]
成分1を含有する液状医薬製剤における成分1の酸化体生成を抑制する方法であって、液状医薬製剤に緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめず、且つ、液状医薬製剤のpHを4.0を超えかつ5.0以下とすると共に、液状医薬製剤に成分3を、成分1と成分3との質量比が1:0.2~1.0となるように含有せしめることを含む方法であり、成分1の酸化体が、テリパラチドのN末端から8番目のメチオニン残基がスルホキシド化されたテリパラチド酸化体又はその塩である、方法。
・成分1)テリパラチド又はその塩。
・成分3)メチオニン。
[34]
成分1を含有する液状医薬製剤における成分1の酸化体生成を抑制する方法であって、液状医薬製剤に成分4を含有せしめることを含む方法であり、成分1の酸化体が、成分1のN末端から23番目に存在するトリプトファン残基が酸化している酸化体であって、その他の残基はテリパラチドの対応する残基と同一である、成分1の酸化体である、方法。
・成分1)テリパラチド又はその塩。
・成分4)D-マンニトール。
[35]
成分1を含有する液状医薬製剤を保存する方法であって、液状医薬製剤はガラス製医療容器に充填され、液状医薬製剤に緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめず、且つ、液状医薬製剤のpHを4.0を超えかつ5.0以下とすることを含む方法。
・成分1)テリパラチド又はその塩。
[36]
成分1を含有する液状医薬製剤を保存する方法であって、液状医薬製剤はプラスチック製医療容器に充填され、液状医薬製剤に緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめ、さらに、液状医薬製剤に成分4を含有せしめ、且つ、液状医薬製剤のpHを4.0を超えかつ5.0以下とすることを含む方法。
・成分1)テリパラチド又はその塩。
・成分4)マンニトール。
[37]
成分1を含有する液状医薬製剤を保存する方法であって、液状医薬製剤に成分5を含有せしめることを含む方法。
・成分1)テリパラチド又はその塩。
・成分5)L-プロリン、ベタイン、エクトイン、ヒドロキシエクトイン、L-アルギニン塩酸塩、L-ヒスチジン、2-ヒドロキシプロピル-β-シクロデキストリン、α-シクロデキストリン、β-シクロデキストリン、γ-シクロデキストリン、N-アセチル-アルギニン、L-リジン塩酸塩、N-アセチル-DL-トリプトファンからなる群より選ばれる1以上の成分。
[38]
成分5が、α-シクロデキストリン、β-シクロデキストリン、N-アセチル-アルギニン、L-プロリン、L-アルギニン塩酸塩、L-リジン塩酸塩からなる群より選ばれる1以上の成分である、[37]に記載の方法。
[39]
成分1のN末端から16番目に存在するアスパラギン残基がイソアスパラギン酸残基に変化した類縁体であって、その他の残基はテリパラチドの対応する残基と同一である、成分1の類縁体。
・成分1)テリパラチド又はその塩。
[40]
成分1のN末端から16番目に存在するアスパラギン残基がアスパラギン酸残基に変化した類縁体であって、その他の残基はテリパラチドの対応する残基と同一である、成分1の類縁体。
・成分1)テリパラチド又はその塩。
[41]
成分1のN末端から30番目に存在するアスパラギン酸残基がイソアスパラギン酸残基に変化した類縁体であって、その他の残基はテリパラチドの対応する残基と同一である、成分1の類縁体。
・成分1)テリパラチド又はその塩。
[42]
成分1のN末端から10番目に存在するアスパラギン残基がアスパラギン酸残基又はイソアスパラギン酸残基に変化した類縁体であって、成分1のN末端から30番目に存在するアスパラギン酸残基がイソアスパラギン酸残基に変化した類縁体であり、その他の残基はテリパラチドの対応する残基と同一である、成分1の類縁体。
・成分1)テリパラチド又はその塩。
[43]
前記[39]~[42]のいずれかに記載の類縁体を検出及び/又は定量する工程を含む、成分1を含有する液状医薬製剤の品質検査方法。
・成分1)テリパラチド又はその塩。
[44]
成分1を含有する液状医薬シリンジ製剤を遮光することにより、同製剤中の酸化体生成を抑制する方法であって、酸化体はテリパラチドのN末端から18番目のメチオニン残基がスルホキシド化されたテリパラチド酸化体又はその塩である、抑制方法。
・成分1)テリパラチド又はその塩。
本発明は、一態様として、成分1)テリパラチド又はその塩、及び、成分2)少なくとも1種以上の無機塩及び/又は有機塩を含有する、液状医薬製剤を提供する。
1)成分1)テリパラチド又はその塩、及び、成分2)少なくとも1種以上の無機塩及び/又は有機塩を含有し、さらに緩衝剤を実質的に含有し、そのpHが5.0未満である、液状医薬製剤。
2)成分1)テリパラチド又はその塩、及び、成分2)少なくとも1種以上の無機塩及び/又は有機塩を含有し、緩衝剤を実質的を含有せず、pHが5.0未満である、液状医薬製剤。
3)成分1)テリパラチド又はその塩、及び、成分2)少なくとも1種以上の無機塩及び/又は有機塩を含有し、緩衝剤を実質的を含有せず、pHが5.0以上である、液状医薬製剤。
4)成分1と成分2との質量比が1:20又は20以上である、前記液状医薬製剤。
5)成分1)テリパラチド又はその塩を含有し、そのpHが3.6~4.1である、前記液状医薬製剤。
6)成分1)テリパラチド又はその塩を含有し、そのpHが4.0~5.0であり、ガラス製医療用容器に充填され、緩衝剤を実質的に含有しない、前記液状医薬製剤。
7)成分1)テリパラチド又はその塩を含有し、そのpHが4.0~5.0であり、プラスチック製医療用容器に充填され、緩衝剤を実質的に含有する、前記液状医薬製剤。
これらの態様に係る本発明のより好ましい具体的態様を以下に列挙する。
1)成分1)テリパラチド又はその塩、及び、成分3)メチオニンを含有し、成分1:成分3が1:0.2~1.0である、液状医薬製剤。
2)成分1)テリパラチド又はその塩、及び、成分4)D-マンニトールを含有する、液状医薬製剤。
3)成分1)テリパラチド又はその塩、及び、成分5)L-プロリン、ベタイン、エクトイン、ヒドロキシエクトイン、L-アルギニン塩酸塩、L-ヒスチジン、2-ヒドロキシプロピル-β-シクロデキストリン、α-シクロデキストリン、β-シクロデキストリン、γ-シクロデキストリン、N-アセチル-アルギニン、L-リジン塩酸塩、N-アセチル-DL-トリプトファンからなる群より選ばれる1以上の成分を含有する、液状医薬製剤。
本発明の液状医薬製剤は、後述のテリパラチド又はその塩(成分1)を含有する液状の医薬製剤であれば、その形態は特に限定されない。例としては、経口投与用製剤(内服剤)又は非経口投与用製剤が挙げられるが、非経口投与用製剤が好ましい。非経口投与用製剤の例としては、外用剤等の局所投与用製剤や注射剤等の全身投与用製剤が挙げられるが、全身投与用製剤が好ましく、特に注射剤が好ましい。また、全身投与の具体的な投与経路としては、静脈内投与、筋肉内投与、皮内投与、皮下投与用等が挙げられるが、皮下投与が好ましい。即ち、本発明の液状医薬製剤として、好ましくは皮下投与用液状医薬製剤又は注射用液状医薬製剤を例示でき、最も好ましくは皮下注射用液状医薬製剤を例示できる。
本発明において、ヒトPTH(1-34)は、ヒト副甲状腺ホルモンであるヒトPTH(1-84)のアミノ酸配列において、N末端側からみて第1番目から第34番目までのアミノ酸残基からなる部分アミノ酸配列で示されるペプチドである。
本発明の液状医薬製剤において、少なくとも1種以上の無機塩及び/又は有機塩が含まれていることが好ましい。このような液状医薬製剤においては、好ましくは、成分1の脱アミド及びアスパラギン酸残基異性化が共に抑制され得る。
本発明に係る緩衝剤は、水溶液のpHを安定化させることができる、医薬分野で一般的に使用されるものであれば特に限定されない。本発明に係る緩衝剤として、例えば、酢酸、酒石酸、乳酸、クエン酸、ホウ酸、リン酸、炭酸及びその塩を挙げることができる。より具体的には、酢酸及び酢酸ナトリウム、クエン酸及びクエン酸三ナトリウム、炭酸水素ナトリウム及び炭酸ナトリウム、リン酸二水素ナトリウム及びリン酸水素二ナトリウムを例示できる。このような緩衝剤が本発明の液状医薬製剤に含まれていてもよい。
本発明の液状医薬製剤には、各種の添加物を含有せしめることもできる。添加物として、例えば、可溶化剤、安定化剤、等張化剤、pH調節剤、防腐剤(保存剤)などを挙げることができる。
本発明の液状医薬製剤にメチオニンを含有せしめることができる。
本発明の液状医薬製剤にD-マンニトールを含有せしめることができる。
本発明の液状医薬製剤には、L-プロリン、ベタイン、エクトイン、ヒドロキシエクトイン、L-アルギニン或いはその塩酸塩、L-ヒスチジン或いはその塩酸塩、2-ヒドロキシプロピル-β-シクロデキストリン、α-シクロデキストリン、β-シクロデキストリン、γ-シクロデキストリン、L-リジン或いはその塩酸塩、N-アセチル-DL-トリプトファン、及び、N-アセチル-アルギニンからなる群より選ばれる1以上の成分(成分5)を含ませることができる。成分5として、α-シクロデキストリン、β-シクロデキストリン、N-アセチル-アルギニン、L-リジン或いはその塩酸塩、L-プロリン、及び、L-アルギニン或いはその塩酸塩からなる群より選ばれる1以上の成分であることが好ましい。このような液状医薬製剤は、長期に安定であり得る。
本発明における液状医薬製剤のpHは特に限定されない。
本発明の液状医薬製剤は、自体公知の種々の製法により製造可能である。通常は、本発明の液状医薬製剤を構成する前述の各種の成分を適宜選択し、適切な溶媒と混合して溶解させればよい。
本発明の液状医薬製剤は、凍結乾燥製剤から再構成されてなる液状医薬製剤の態様を含んでもよい。また、本発明の液状医薬製剤は、凍結乾燥製剤から再構成されてなる液状医薬製剤ではなくてもよい。従来、テリパラチド又はその塩を含有する凍結乾燥製剤を用時に生理食塩水等に溶解させて液状医薬製剤とすることが知られているが、本発明の液状医薬製剤は、このような凍結乾燥製剤の再溶解品(用時調製品)であってもよく、このような凍結乾燥製剤を経ない製剤(予め液剤化された製剤)であってもよい。
脱アミドは、対象となる有機化合物におけるアミドが非酵素的に取り除かれる反応を意味する。タンパク質やペプチド(以降、タンパク質等と称することもある。)には、アスパラギン残基やグルタミン残基を含むものもあるが、いずれの残基も側鎖にアミドを有しており、このアミドが取り除かれる反応も脱アミドに含まれる(非特許文献6)。タンパク質等の医薬製剤におけるタンパク質等の分解とそれに続く活性の低減は、医薬品産業において重要な課題を与え得る。
テリパラチド又はその塩(成分1)のアスパラギン酸残基の異性化とは、テリパラチド又はその塩のアミノ酸配列において、N末端から30番目のアスパラギン酸残基がイソアスパラギン酸残基に変化する反応であることができる。アスパラギン酸残基からイソアスパラギン酸残基への構造変化は当業者であれば理解し得て(非特許文献8など)、周知技術を用いてその反応を検出及び定量することができる。
PTHを水溶液剤とした場合、その保存安定性は悪く、この問題点を回避することは肝要である(特許文献2)。また、タンパク質等の医薬製剤におけるタンパク質等の分解とそれに続く活性の低減は、医薬品産業において重要な課題を与え得る。
テリパラチド水溶液にメチオニンを添加するとテリパラチドが安定化することや放射線滅菌した樹脂製のプレフィルドシリンジに充填したテリパラチド水溶液が同液に含まれるメチオニンによって安定化されることも知られている(特許文献2~3)。
PTHを水溶液剤とした場合、その保存安定性は悪く、この問題点を回避することは肝要である(特許文献2)。したがって、テリパラチド又はその塩(成分1)を含有する液状医薬製剤の品質を管理する新たな方法の提供は有用である。
脱アミド体(N16→iso-D16)とは、テリパラチドのN末端から16番目に存在するアスパラギン残基がイソアスパラギン酸残基に変化した脱アミド体であって、その他の残基はテリパラチドの対応する残基と同一である、脱アミド体を意味する。
脱アミド体(N16→D16)とは、テリパラチドのN末端から16番目に存在するアスパラギン残基がアスパラギン酸残基に変化した脱アミド体であって、その他の残基はテリパラチドの対応する残基と同一である、脱アミド体を意味する。
Asp異性化体(D30→iso-D30)とは、テリパラチドのN末端から30番目に存在するアスパラギン酸残基がイソアスパラギン酸残基に変化した異性化体であって、その他の残基はテリパラチドの対応する残基と同一である、異性化体を意味する。
脱アミド体(N10)-Asp異性化体(D30→iso-D30)とは、テリパラチドのN末端から10番目に存在するアスパラギン残基が脱アミドされて生成された脱アミド体であって、その結果、同残基がアスパラギン酸残基又はイソアスパラギン酸残基に変化してなる脱アミド体であり、かつ、テリパラチドのN末端から30番目に存在するアスパラギン酸残基がイソアスパラギン酸残基に変化してなるアスパラギン酸残基異性化体を意味する。
遮光保存を要する医療用医薬品は、少なくとも数千品目程度存在しており、医薬製剤の適正管理のために十分に光安定な条件の下で保存されることが好ましい。
(1)脱アミド体及びアスパラギン酸残基異性化体の生成抑制試験に供した液状医薬製剤の調製:
(1-1)製造1:
下記表1に従って処方1~11を調製した。
下記表2に従って対照処方12~対照処方17を調製した。
下記表3に従って処方18~処方29を調製した。
下記表4に従って処方30~32を調製した。
下記表5に従って処方33~40を調製した。
下記表6に従って処方41及び処方42を調製した。
下記表7に従って処方43~処方59を調製した。
各処方の具体的調製法は次の通りである。表中の「添加物」欄記載のテリパラチド量を秤量した後に、表中の「溶媒」欄記載の溶媒により溶解をし、表中の「メスアップ」欄記載の容量にメスアップすることで各処方を調製した。
下記表9に従って処方62を調製した。
(1)試験方法:
前述の「脱アミド体及びアスパラギン酸残基異性化体の生成抑制試験に供した液状医薬製剤」において調製された処方1~29製剤を用いて脱アミド体及びアスパラギン酸残基異性化体の生成抑制試験を実施した。
試験結果を以下の表10~14に記す。表中の数値は処方に含まれるテリパラチド及びその類縁物質の総量を100とした場合の割合(%)を示す。
(1)試験方法:
前述の「メチオニンの効果試験に供した液状医薬製剤」において調製された処方30~32製剤を用いて、メチオニンの効果試験を実施した。
試験結果を以下の表15及び16に記す。
表中の「類縁物質量」は、処方に含まれるテリパラチド及びその類縁物質の総量を100とした場合の割合(%)を示す。ただし、表中の「対開始時含量」とは、保存前のテリパラチド量を100とした場合の6箇月目に残存していたテリパラチド量の割合(%)を示す。
(1)試験方法:
前述の「充填容器に関する安定性試験に供した液状医薬製剤」において調製された処方33~40アンプル製剤、及び、前述の「充填容器に関する安定性試験に供した液状医薬製剤」において調製された処方33~40シリンジ製剤を用いて、安定性試験を実施した。
試験結果を以下の表17及び表18に記す。
表中の「対開始時含量」とは、保存前のテリパラチド量を100とした場合の3箇月目に残存していたテリパラチド量の割合(%)を示す。表中の「類縁物質総量」とは、3箇月目に存在している(テリパラチド量及び類縁物質総量)を100とした場合の3箇月目に存在している類縁物質総量の割合(%)を示す。
(1)試験方法:
前述の「対照比較に関する安定性試験に供した液状医薬製剤」において調製された処方41~42製剤、及び、前述の「充填容器に関する安定性試験に供した液状医薬製剤」において調製された処方38シリンジ製剤を用いて、安定性試験を実施した。
試験結果を以下の表19に記す。
表中の「対開始時含量(3ヵ月保存後)」とは、保存前のテリパラチド量を100とした場合の3箇月目に残存していたテリパラチド量の割合(%)を示す。表中の「類縁物質総量(3ヵ月保存後)」とは、3箇月目に存在している(テリパラチド量及び類縁物質総量)を100とした場合の3箇月目に存在している類縁物質総量の割合(%)を示す。
(1)試験方法:
前述の「充填容器に関する安定性試験に供した液状医薬製剤の調製」において調製された処方33、38製剤、及び、前述の「対照液状医薬製剤の調製」において調製された処方62製剤を用いて特定類縁体抑制に関する安定性試験を実施した。
(2)カラム:内径4.6mm、長さ150mmのステンレス管に3.5μmの液体ク
ロマトグラフィー用オクタデシルシリル化シリカゲルを充填(Agilent Tech
nologies社製のZorbax 300SB-C18、又は同等品)
(3)カラム温度:40℃付近の一定温度
(4)移動相
移動相A:無水硫酸ナトリウム28.4gを水900mLに溶かし、リン酸を加えてpH2.3に調整した後、水を加えて1000mLとする。この液900mLにアセトニトリル100mLを加える。
移動相B:無水硫酸ナトリウム28.4gを水900mLに溶かし、リン酸を加えてpH2.3に調整した後、水を加えて1000mLとする。この液500mLにアセトニトリル500mLを加える。
(5)移動相の送液
移動相A及び移動相Bの混合比を下記表20のように変えて濃度勾配制御する。
(7)検出時間:試料溶液注入後45分間。ただし溶媒ピークの後ろからとする。
各処方の相対保持時間0.72の類縁物質の量を下記表21に示す。
表中の「開始時含量」とは、保存前の(テリパラチド量及び類縁物質総量)を100とした場合に存在していた相対保持時間0.72の類縁物質量の割合(%)を示す。表中の「3箇月含量」とは、3箇月目に存在している(テリパラチド量及び類縁物質総量)を100とした場合の3箇月目に存在している相対保持時間0.72の類縁物質量の割合(%)を示す。
(1)試験方法:
前述の「添加剤評価に関する安定性試験に供した液状医薬製剤の調製」において調製された処方43~61を用いて添加剤評価に関する安定性試験を実施した。
試験結果を以下の表22に示す。
表中において「-」は、測定されなかった事実を意味する。
(1)試験方法:
前述の「充填容器に関する安定性試験に供した液状医薬製剤」において調製された処方38シリンジ製剤又は紙箱等で包装された同製剤を、市販の光安定性試験装置に供し、D65ランプを光源として(照度:2500lx)、5℃±3℃の条件の下、120万lx・hr以上かつ200w・h/m2を満たす期間として20日間、又は、60万lx・hr以上を満たす期間として10日間にわたり、曝光した。曝光後、サンプリングを行い、高速液体クロマトグラフィーにより製剤中の類縁体総量ならびに8酸化体および18酸化体を測定した。ここで、紙箱等で包装された同製剤とは、シリンジ製剤をデバイスに組み込み、そのデバイスをさらにブリスター包装し、個装箱に内包させたものである。
Claims (44)
- 成分1及び成分2を含有する液状医薬製剤。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。 - pHが5.0未満である、請求項1に記載の液状医薬製剤。
- 成分1及び成分2を含有する液状医薬製剤であって、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有する液状医薬製剤(ただし、pHは5.0未満である。)。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。 - 成分1及び成分2を含有する液状医薬製剤であって、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有しない液状医薬製剤(ただし、pHは5.0未満である。)。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。 - 成分1及び成分2を含有する液状医薬製剤であって、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有しない液状医薬製剤(ただし、pHは5.0以上である。)。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。 - 成分1と成分2との質量比が1:20又は20以上である、請求項1~5のいずれか1項に記載の液状医薬製剤。
- 成分1を含有する液状医薬製剤であって、pHが3.6~4.1である、液状医薬製剤。
・成分1)テリパラチド又はその塩。 - 成分1及び成分3を含有する液状医薬製剤であって、成分1と成分3との質量比が1:0.2~1.0である、液状医薬製剤。
・成分1)テリパラチド又はその塩。
・成分3)メチオニン。 - 成分1及び成分4を含有する、液状医薬製剤。
・成分1)テリパラチド又はその塩。
・成分4)D-マンニトール。 - ガラス製医療用容器に充填されている、成分1を含有する液状医薬製剤であって、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含まず、かつ、pHが4.0を超え5.0以下である、液状医薬製剤;
・成分1)テリパラチド又はその塩。 - プラスチック製医療用容器に充填されている、成分1を含有する液状医薬製剤であって、pHが4.0~4.2であり、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含み、さらに、成分4を含有する、液状医薬製剤;
・成分1)テリパラチド又はその塩。
・成分4)D-マンニトール。 - 成分1及び成分5を含有する液状医薬製剤。
・成分1)テリパラチド又はその塩。
・成分5)L-プロリン、ベタイン、エクトイン、ヒドロキシエクトイン、L-アルギニン塩酸塩、L-ヒスチジン、2-ヒドロキシプロピル-β-シクロデキストリン、α-シクロデキストリン、β-シクロデキストリン、γ-シクロデキストリン、N-アセチル-アルギニン、L-リジン塩酸塩、及び、N-アセチル-DL-トリプトファンからなる群より選ばれる1以上の成分。 - 成分5が、α-シクロデキストリン、β-シクロデキストリン、N-アセチル-アルギニン、L-プロリン、L-アルギニン塩酸塩、及び、L-リジン塩酸塩からなる群より選ばれる1以上の成分である、請求項12に記載の液状医薬製剤。
- 成分2が、塩化ナトリウム、塩化カルシウム、塩化マグネシウム、臭化ナトリウム、酢酸ナトリウム、クエン酸三ナトリウム及び炭酸ナトリウムから選択される1種以上の塩である、請求項1~6に記載の液状医薬製剤。
- 成分2が塩化ナトリウム及び/又はクエン酸三ナトリウムである、請求項14に記載の液状医薬製剤。
- pHが4.1以上4.6以下である、請求項3又は4に記載の液状医薬製剤。
- pHが5.0である、請求項5に記載の液状医薬製剤。
- 成分1がテリパラチド酢酸塩である、請求項1~17のいずれか1項に記載の液状医薬製剤。
- 成分1含有量がテリパラチド換算で25~30μgである、請求項1~18のいずれか1項に記載の液状医薬製剤。
- ヒト皮下投与用である、請求項1~19のいずれか1項に記載の液状医薬製剤。
- 成分1を含む液状医薬製剤における成分1の脱アミド反応を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめることを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。 - 液状医薬製剤のpHが5.0未満である、請求項21に記載の方法。
- pH5.0未満の条件下、成分1を含む液状医薬製剤における成分1の脱アミド反応を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめると共に、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめることを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。 - pH5.0未満の条件下、成分1を含む液状医薬製剤における成分1の脱アミド反応を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめると共に、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめないことを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。 - pH5.0以上の条件下、成分1を含む液状医薬製剤における成分1の脱アミド反応を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめると共に、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめないことを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。 - 脱アミド反応の抑制が、成分1のN末端から16番目に位置するアスパラギン残基がイソアスパラギン酸残基に変化してなる成分1の脱アミド体の生成の抑制である、請求項25に記載の方法。
- 成分2が、塩化ナトリウム、塩化カルシウム、塩化マグネシウム、臭化ナトリウム、酢酸ナトリウム、クエン酸三ナトリウム及び炭酸ナトリウムから選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)である、請求項21~26のいずれか1項に記載の方法。
- 成分1を含む液状医薬製剤における成分1の脱アミド反応を抑制する方法であって、液状医薬製剤のpHを3.6~4.1とすることを手段とする方法;
・成分1)テリパラチド又はその塩。 - 成分1を含む液状医薬製剤における成分1のアスパラギン酸残基の異性化を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめることを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。 - 成分1を含む液状医薬製剤における成分1のアスパラギン酸残基の異性化を抑制する方法であって、液状医薬製剤に更に成分2を含有せしめると共に、緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめることを含む方法。
・成分1)テリパラチド又はその塩。
・成分2)ナトリウム塩、カルシウム塩、及びマグネシウム塩から選択される1種以上の塩、及び/又は、塩酸塩、臭化水素酸塩、酢酸塩、クエン酸塩及び炭酸塩から選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)。 - アスパラギン酸残基の異性化の抑制が、成分1のN末端から30番目に位置するアスパラギン酸残基がイソアスパラギン酸残基に変化してなる成分1のアスパラギン酸残基の異性化の抑制である、請求項30に記載の方法。
- 成分2が、塩化ナトリウム、塩化カルシウム、塩化マグネシウム、臭化ナトリウム、酢酸ナトリウム、クエン酸三ナトリウム及び炭酸ナトリウムから選択される1種以上の塩(ただし、成分2は成分1とは異なる成分である。)である、請求項29~31のいずれか1項に記載の方法。
- 成分1を含有する液状医薬製剤における成分1の酸化体生成を抑制する方法であって、液状医薬製剤に緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめず、且つ、液状医薬製剤のpHを4.0を超えかつ5.0以下とすると共に、液状医薬製剤に成分3を、成分1と成分3との質量比が1:0.2~1.0となるように含有せしめることを含む方法であり、成分1の酸化体が、テリパラチドのN末端から8番目のメチオニン残基がスルホキシド化されたテリパラチド酸化体又はその塩である、方法。
・成分1)テリパラチド又はその塩。
・成分3)メチオニン。 - 成分1を含有する液状医薬製剤における成分1の酸化体生成を抑制する方法であって、液状医薬製剤に成分4を含有せしめることを含む方法であり、成分1の酸化体が、成分1のN末端から23番目に存在するトリプトファン残基が酸化している酸化体であって、その他の残基はテリパラチドの対応する残基と同一である、成分1の酸化体である、方法。
・成分1)テリパラチド又はその塩。
・成分4)D-マンニトール。 - 成分1を含有する液状医薬製剤を保存する方法であって、液状医薬製剤はガラス製医療容器に充填され、液状医薬製剤に緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめず、且つ、液状医薬製剤のpHを4.0を超えかつ5.0以下とすることを含む方法。
・成分1)テリパラチド又はその塩。 - 成分1を含有する液状医薬製剤を保存する方法であって、液状医薬製剤はプラスチック製医療容器に充填され、液状医薬製剤に緩衝剤(ただし、成分1がテリパラチド塩である場合、成分1から脱離する塩は、ここでの緩衝剤には相当しない。)を実質的に含有せしめ、さらに、液状医薬製剤に成分4を含有せしめ、且つ、液状医薬製剤のpHを4.0を超えかつ5.0以下とすることを含む方法。
・成分1)テリパラチド又はその塩。
・成分4)マンニトール。 - 成分1を含有する液状医薬製剤を保存する方法であって、液状医薬製剤に成分5を含有せしめることを含む方法。
・成分1)テリパラチド又はその塩。
・成分5)L-プロリン、ベタイン、エクトイン、ヒドロキシエクトイン、L-アルギニン塩酸塩、L-ヒスチジン、2-ヒドロキシプロピル-β-シクロデキストリン、α-シクロデキストリン、β-シクロデキストリン、γ-シクロデキストリン、N-アセチル-アルギニン、L-リジン塩酸塩、N-アセチル-DL-トリプトファンからなる群より選ばれる1以上の成分。 - 成分5が、α-シクロデキストリン、β-シクロデキストリン、N-アセチル-アルギニン、L-プロリン、L-アルギニン塩酸塩、L-リジン塩酸塩からなる群より選ばれる1以上の成分である、請求項37に記載の方法。
- 成分1のN末端から16番目に存在するアスパラギン残基がイソアスパラギン酸残基に変化した類縁体であって、その他の残基はテリパラチドの対応する残基と同一である、成分1の類縁体。
・成分1)テリパラチド又はその塩。 - 成分1のN末端から16番目に存在するアスパラギン残基がアスパラギン酸残基に変化した類縁体であって、その他の残基はテリパラチドの対応する残基と同一である、成分1の類縁体。
・成分1)テリパラチド又はその塩。 - 成分1のN末端から30番目に存在するアスパラギン酸残基がイソアスパラギン酸残基に変化した類縁体であって、その他の残基はテリパラチドの対応する残基と同一である、成分1の類縁体。
・成分1)テリパラチド又はその塩。 - 成分1のN末端から10番目に存在するアスパラギン残基がアスパラギン酸残基又はイソアスパラギン酸残基に変化した類縁体であって、成分1のN末端から30番目に存在するアスパラギン酸残基がイソアスパラギン酸残基に変化した類縁体であり、その他の残基はテリパラチドの対応する残基と同一である、成分1の類縁体。
・成分1)テリパラチド又はその塩。 - 請求項39~42のいずれか1項に記載の類縁体を検出及び/又は定量する工程を含む、成分1を含有する液状医薬製剤の品質検査方法。
・成分1)テリパラチド又はその塩。 - 成分1を含有する液状医薬シリンジ製剤を遮光することにより、同製剤中の酸化体生成を抑制する方法であって、酸化体はテリパラチドのN末端から18番目のメチオニン残基がスルホキシド化されたテリパラチド酸化体又はその塩である、抑制方法。
・成分1)テリパラチド又はその塩。
Priority Applications (7)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2018558440A JP6577683B2 (ja) | 2017-09-22 | 2018-09-20 | 安定性に優れるテリパラチド含有液状医薬組成物 |
EP18859204.2A EP3685849A4 (en) | 2017-09-22 | 2018-09-20 | LIQUID PHARMACEUTICAL COMPOSITION CONTAINING TRIPARATIDE WITH EXCELLENT STABILITY |
CN201880053788.9A CN110996988A (zh) | 2017-09-22 | 2018-09-20 | 稳定性优异的含有特立帕肽的液态药物组合物 |
CA3075977A CA3075977A1 (en) | 2017-09-22 | 2018-09-20 | Teriparatide-containing liquid pharmaceutical composition having excellent stability |
US16/649,254 US20200289621A1 (en) | 2017-09-22 | 2018-09-20 | Teriparatide-containing liquid pharmaceutical composition having excellent stability |
CN202311111773.2A CN116898955A (zh) | 2017-09-22 | 2018-09-20 | 稳定性优异的含有特立帕肽的液态药物组合物 |
US17/206,987 US20210205418A1 (en) | 2017-09-22 | 2021-03-19 | Teriparatide-containing liquid pharmaceutical composition having excellent stability |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2017-182611 | 2017-09-22 | ||
JP2017182611 | 2017-09-22 |
Related Child Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US16/649,254 A-371-Of-International US20200289621A1 (en) | 2017-09-22 | 2018-09-20 | Teriparatide-containing liquid pharmaceutical composition having excellent stability |
US17/206,987 Division US20210205418A1 (en) | 2017-09-22 | 2021-03-19 | Teriparatide-containing liquid pharmaceutical composition having excellent stability |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2019059302A1 true WO2019059302A1 (ja) | 2019-03-28 |
Family
ID=65811407
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2018/034887 WO2019059302A1 (ja) | 2017-09-22 | 2018-09-20 | 安定性に優れるテリパラチド含有液状医薬組成物 |
Country Status (6)
Country | Link |
---|---|
US (2) | US20200289621A1 (ja) |
EP (1) | EP3685849A4 (ja) |
JP (17) | JP6577683B2 (ja) |
CN (2) | CN116898955A (ja) |
CA (1) | CA3075977A1 (ja) |
WO (1) | WO2019059302A1 (ja) |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021117735A1 (ja) * | 2019-12-09 | 2021-06-17 | 旭化成ファーマ株式会社 | テリパラチド又はその塩を含有するプレフィルドシリンジまたはカートリッジ製剤の振盪による白濁を抑制する方法 |
JP2021178830A (ja) * | 2020-05-11 | 2021-11-18 | 旭化成ファーマ株式会社 | テリパラチド又はその塩を含有する安定な液状医薬製剤 |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP6577683B2 (ja) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
JP7240407B2 (ja) * | 2019-09-05 | 2023-03-15 | 旭化成ファーマ株式会社 | テリパラチド又はその塩を含有する無菌注射剤を製造する方法 |
AU2020409932B2 (en) * | 2019-12-18 | 2023-09-07 | Daewoong Pharmaceutical Co., Ltd. | Liquid pharmaceutical composition of 1-(5-(2,4-difluorophenyl)-1-((3-fluorophenyl)sulfonyl)-4-methoxy-1H-pyrrole-3-yl)-N-methylmethaneamine |
CN114306249A (zh) * | 2020-09-28 | 2022-04-12 | 深圳翰宇药业股份有限公司 | 一种特立帕肽冻干药物组合物及其制备方法 |
CN114031680B (zh) * | 2021-09-01 | 2024-03-26 | 浙江湃肽生物有限公司 | 一种索玛鲁肽钠盐及其制备方法与应用 |
CN114316021A (zh) * | 2021-12-29 | 2022-04-12 | 江苏诺泰澳赛诺生物制药股份有限公司 | 一种特立帕肽及的纯化方法 |
Citations (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6357527A (ja) | 1986-08-28 | 1988-03-12 | Toyo Jozo Co Ltd | 薬剤の吸着防止方法 |
JPH0296533A (ja) | 1988-09-30 | 1990-04-09 | Toyo Jozo Co Ltd | ポリペプタイド類の吸着防止剤 |
JPH05306235A (ja) | 1991-12-09 | 1993-11-19 | Asahi Chem Ind Co Ltd | パラサイロイドホルモン類の安定化組成物 |
EP0920873A2 (en) | 1997-12-09 | 1999-06-09 | Eli Lilly And Company | Stabilized teriparatide solutions |
JP2002512973A (ja) * | 1998-04-28 | 2002-05-08 | エヌピーエス アレリックス コーポレーション | タンパク質製剤 |
JP2004010511A (ja) | 2002-06-05 | 2004-01-15 | Asahi Kasei Corp | Pthの安定化水溶液注射剤 |
JP2004513069A (ja) | 2000-05-19 | 2004-04-30 | レストラゲン,インコーポレイテッド | ペプチド医薬処方 |
JP2004529342A (ja) * | 2001-04-03 | 2004-09-24 | アーベーツェー アルムブルスター バイオケミカルズ | 試料中の実効的な副甲状腺ホルモン活性の測定方法 |
JP2005213158A (ja) | 2004-01-27 | 2005-08-11 | Asahi Kasei Pharma Kk | ポリペプタイド類の吸着防止剤 |
JP2007186466A (ja) | 2006-01-16 | 2007-07-26 | Asahi Kasei Pharma Kk | 樹脂容器中の生理活性ペプチドの安定性改善方法 |
JP2009511472A (ja) * | 2005-10-06 | 2009-03-19 | エムディーアールエヌエー,インコーポレイテッド | Pth剤形及びその使用方法 |
JP2010501476A (ja) * | 2006-07-31 | 2010-01-21 | ゼロス セラピューティクス, インコーポレイテッド | 副甲状腺ホルモン類似体およびその使用方法 |
WO2011011675A1 (en) | 2009-07-23 | 2011-01-27 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
WO2011030774A1 (ja) * | 2009-09-09 | 2011-03-17 | 旭化成ファーマ株式会社 | 1回当たり100~200単位のpthが週1回投与されることを特徴とする、pth含有骨粗鬆症治療/予防剤 |
WO2011139838A2 (en) | 2010-04-28 | 2011-11-10 | Zelos Therapeutics, Inc. | Intranasal formulations |
JP2012522059A (ja) | 2009-03-30 | 2012-09-20 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 口腔ケアシステムのためのペプチド組成物 |
WO2012169435A1 (ja) | 2011-06-07 | 2012-12-13 | 旭化成ファーマ株式会社 | 高純度pth含有凍結乾燥製剤およびその製造方法 |
WO2013108235A1 (en) | 2012-01-20 | 2013-07-25 | Lupin Limited | Stabilized pth formulation |
JP2014507484A (ja) | 2011-03-10 | 2014-03-27 | ゼリス ファーマシューティカルズ インコーポレイテッド | ペプチド薬物の非経口注射用の安定な製剤 |
JP2017061424A (ja) * | 2015-09-25 | 2017-03-30 | ニプロ株式会社 | 液体組成物及び凍結乾燥製剤 |
Family Cites Families (39)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL9001681A (nl) * | 1990-07-24 | 1992-02-17 | Rijksuniversiteit | Transmucosale geneesmiddelpreparaten en transmucosale toediening. |
US6673335B1 (en) * | 1992-07-08 | 2004-01-06 | Nektar Therapeutics | Compositions and methods for the pulmonary delivery of aerosolized medicaments |
JPH11292787A (ja) * | 1995-08-15 | 1999-10-26 | Asahi Chem Ind Co Ltd | 生理活性ペプチドを含有する経粘膜投与製剤 |
DE19538687A1 (de) * | 1995-10-17 | 1997-04-24 | Boehringer Mannheim Gmbh | Stabile pharmazeutische Darreichungsformen enthaltend Parathormon |
JPH11235390A (ja) * | 1997-12-12 | 1999-08-31 | Takeda Chem Ind Ltd | 経皮透過方法 |
PL341209A1 (en) * | 1997-12-18 | 2001-03-26 | Lilly Co Eli | Crystalline teriparatide |
DZ2873A1 (fr) * | 1998-08-19 | 2003-12-15 | Lilly Co Eli | Procédé pour augmenter la dureté et la rigidité osseuse. |
JP2000247903A (ja) * | 1999-03-01 | 2000-09-12 | Chugai Pharmaceut Co Ltd | 長期安定化製剤 |
WO2001087322A2 (en) * | 2000-05-17 | 2001-11-22 | Bionebraska, Inc. | Peptide pharmaceutical formulations |
MXPA03002993A (es) * | 2000-10-09 | 2003-07-14 | Lilly Co Eli | Dispositivo en forma de pluma para administracion de hormona paratiroides. |
EP1391209A4 (en) * | 2001-05-30 | 2009-12-16 | Chugai Pharmaceutical Co Ltd | PROTEIN PREPARATION |
US6896894B2 (en) * | 2001-10-30 | 2005-05-24 | Battelle Memorial Institute | Proteins stabilized with polysaccharide gums |
AU2002363412A1 (en) * | 2001-11-05 | 2003-05-19 | Eli Lilly And Company | Method for improving stability of a bone-connecting implant |
JP4607010B2 (ja) * | 2003-02-28 | 2011-01-05 | 中外製薬株式会社 | タンパク質含有安定化製剤 |
WO2005014034A1 (en) * | 2003-07-14 | 2005-02-17 | Nps Allelix Corp. | Stabilized formulation of parathyroid hormone |
JP2007537274A (ja) * | 2004-05-10 | 2007-12-20 | ナステック ファーマスーティカル カンパニー インク. | 副甲状腺ホルモンの粘膜送達を増強するための組成物及び方法 |
CN100566669C (zh) * | 2004-05-13 | 2009-12-09 | 阿尔扎公司 | 甲状旁腺激素药物的透皮释放装置 |
AU2005244734A1 (en) * | 2004-05-13 | 2005-12-01 | Alza Corporation | Apparatus and method for transdermal delivery of parathyroid hormone agents |
BRPI0514408B8 (pt) * | 2004-08-24 | 2021-05-25 | Asubio Pharma Co Ltd | preparação liquida de peptídeo fisiologicamente ativo |
KR100700869B1 (ko) * | 2005-06-03 | 2007-03-29 | 재단법인 목암생명공학연구소 | Pth, 완충제 및 안정제를 포함하는 안정한 pth조성물 |
US20110046059A1 (en) * | 2005-09-06 | 2011-02-24 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
WO2007044375A2 (en) * | 2005-10-06 | 2007-04-19 | Nastech Pharmaceutical Company Inc. | Pth formulations and methods of use |
WO2008124166A2 (en) * | 2007-04-09 | 2008-10-16 | The Board Of Trustees Of The University Of Arkansas | Fusion proteins of collagen-binding domain and parathyroid hormone |
JP5362715B2 (ja) * | 2007-06-29 | 2013-12-11 | アドバンスト・テクノロジーズ・アンド・リジェネレイティブ・メディスン・エルエルシー | 高温で使用するためのgdf−5を含む液体タンパク質製剤 |
EP2052736A1 (en) * | 2007-10-26 | 2009-04-29 | Nycomed Danmark ApS | Parathyroid hormone formulations und uses thereof |
CA2720845A1 (en) * | 2008-04-14 | 2009-10-22 | Advanced Technologies And Regenerative Medicine, Llc | Liquid buffered gdf-5 formulations |
EP2334323A2 (en) * | 2008-09-10 | 2011-06-22 | F. Hoffmann-La Roche AG | Compositions and methods for the prevention of oxidative degradation of proteins |
AU2015201581B2 (en) * | 2008-09-17 | 2017-03-09 | Amryt Endo, Inc. | Pharmaceutical Compositions and Related Methods of Delivery |
CN107184976A (zh) * | 2008-11-20 | 2017-09-22 | 弗·哈夫曼-拉罗切有限公司 | 治疗性蛋白质制剂 |
JP2009091363A (ja) * | 2008-11-21 | 2009-04-30 | Asahi Kasei Pharma Kk | Pthの安定化水溶液注射剤 |
WO2012075375A1 (en) * | 2010-12-02 | 2012-06-07 | Lanco Biosciences, Inc. | Delivery of parathyroid hormones by microinjection systems |
US9474689B2 (en) * | 2011-10-25 | 2016-10-25 | Corning Incorporated | Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients |
SG10201608382QA (en) * | 2012-04-09 | 2016-12-29 | Daiichi Sankyo Co Ltd | Anti-fgfr2 antibody |
CN103301058A (zh) * | 2013-06-17 | 2013-09-18 | 深圳翰宇药业股份有限公司 | 一种特立帕肽注射用组合物及其制备方法和制剂 |
EA038462B1 (ru) * | 2014-10-23 | 2021-08-31 | Эмджен Инк. | Снижение вязкости фармацевтических составов |
US20180161401A1 (en) * | 2015-07-06 | 2018-06-14 | Zheng Xin Dong | Novel Formulations of PTHrP Analogue |
JP6641870B2 (ja) * | 2015-10-14 | 2020-02-05 | ニプロ株式会社 | パラサイロイドホルモン類含有製剤の製造方法 |
JP2018188399A (ja) * | 2017-05-10 | 2018-11-29 | ニプロ株式会社 | テリパラチドのプレフィルドシリンジ製剤 |
JP6577683B2 (ja) * | 2017-09-22 | 2019-09-18 | 旭化成ファーマ株式会社 | 安定性に優れるテリパラチド含有液状医薬組成物 |
-
2018
- 2018-09-20 JP JP2018558440A patent/JP6577683B2/ja active Active
- 2018-09-20 EP EP18859204.2A patent/EP3685849A4/en active Pending
- 2018-09-20 CN CN202311111773.2A patent/CN116898955A/zh active Pending
- 2018-09-20 US US16/649,254 patent/US20200289621A1/en not_active Abandoned
- 2018-09-20 CA CA3075977A patent/CA3075977A1/en active Pending
- 2018-09-20 CN CN201880053788.9A patent/CN110996988A/zh active Pending
- 2018-09-20 WO PCT/JP2018/034887 patent/WO2019059302A1/ja unknown
-
2019
- 2019-01-22 JP JP2019008797A patent/JP6714738B2/ja active Active
- 2019-01-22 JP JP2019008790A patent/JP6585317B2/ja active Active
- 2019-03-06 JP JP2019041011A patent/JP6817358B2/ja active Active
- 2019-03-06 JP JP2019040987A patent/JP6826140B2/ja active Active
- 2019-03-25 JP JP2019057434A patent/JP6646173B2/ja active Active
- 2019-03-25 JP JP2019057398A patent/JP6581741B2/ja active Active
- 2019-03-25 JP JP2019057408A patent/JP6634175B2/ja active Active
- 2019-03-25 JP JP2019057438A patent/JP2019089865A/ja active Pending
- 2019-03-25 JP JP2019057412A patent/JP6781790B2/ja active Active
- 2019-04-26 JP JP2019085817A patent/JP6825034B2/ja active Active
- 2019-12-19 JP JP2019228968A patent/JP6739612B2/ja active Active
-
2020
- 2020-03-24 JP JP2020053255A patent/JP6766286B2/ja active Active
- 2020-08-20 JP JP2020139570A patent/JP6818928B2/ja active Active
- 2020-12-03 JP JP2020201121A patent/JP6851536B2/ja active Active
- 2020-12-28 JP JP2020218741A patent/JP6977137B2/ja active Active
-
2021
- 2021-03-09 JP JP2021036829A patent/JP2021088606A/ja active Pending
- 2021-03-19 US US17/206,987 patent/US20210205418A1/en active Pending
Patent Citations (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPS6357527A (ja) | 1986-08-28 | 1988-03-12 | Toyo Jozo Co Ltd | 薬剤の吸着防止方法 |
JPH0296533A (ja) | 1988-09-30 | 1990-04-09 | Toyo Jozo Co Ltd | ポリペプタイド類の吸着防止剤 |
JPH05306235A (ja) | 1991-12-09 | 1993-11-19 | Asahi Chem Ind Co Ltd | パラサイロイドホルモン類の安定化組成物 |
EP0920873A2 (en) | 1997-12-09 | 1999-06-09 | Eli Lilly And Company | Stabilized teriparatide solutions |
JP2001525372A (ja) | 1997-12-09 | 2001-12-11 | イーライ・リリー・アンド・カンパニー | 安定化テリパラチド溶液剤 |
JP2002512973A (ja) * | 1998-04-28 | 2002-05-08 | エヌピーエス アレリックス コーポレーション | タンパク質製剤 |
JP2004513069A (ja) | 2000-05-19 | 2004-04-30 | レストラゲン,インコーポレイテッド | ペプチド医薬処方 |
JP2004529342A (ja) * | 2001-04-03 | 2004-09-24 | アーベーツェー アルムブルスター バイオケミカルズ | 試料中の実効的な副甲状腺ホルモン活性の測定方法 |
JP2004010511A (ja) | 2002-06-05 | 2004-01-15 | Asahi Kasei Corp | Pthの安定化水溶液注射剤 |
JP2005213158A (ja) | 2004-01-27 | 2005-08-11 | Asahi Kasei Pharma Kk | ポリペプタイド類の吸着防止剤 |
JP2009511472A (ja) * | 2005-10-06 | 2009-03-19 | エムディーアールエヌエー,インコーポレイテッド | Pth剤形及びその使用方法 |
JP2007186466A (ja) | 2006-01-16 | 2007-07-26 | Asahi Kasei Pharma Kk | 樹脂容器中の生理活性ペプチドの安定性改善方法 |
JP2010501476A (ja) * | 2006-07-31 | 2010-01-21 | ゼロス セラピューティクス, インコーポレイテッド | 副甲状腺ホルモン類似体およびその使用方法 |
JP2012522059A (ja) | 2009-03-30 | 2012-09-20 | イー・アイ・デュポン・ドウ・ヌムール・アンド・カンパニー | 口腔ケアシステムのためのペプチド組成物 |
WO2011011675A1 (en) | 2009-07-23 | 2011-01-27 | Zelos Therapeutics, Inc. | Pharmaceutically acceptable formulations/compositions for peptidyl drugs |
WO2011030774A1 (ja) * | 2009-09-09 | 2011-03-17 | 旭化成ファーマ株式会社 | 1回当たり100~200単位のpthが週1回投与されることを特徴とする、pth含有骨粗鬆症治療/予防剤 |
WO2011139838A2 (en) | 2010-04-28 | 2011-11-10 | Zelos Therapeutics, Inc. | Intranasal formulations |
JP2014507484A (ja) | 2011-03-10 | 2014-03-27 | ゼリス ファーマシューティカルズ インコーポレイテッド | ペプチド薬物の非経口注射用の安定な製剤 |
WO2012169435A1 (ja) | 2011-06-07 | 2012-12-13 | 旭化成ファーマ株式会社 | 高純度pth含有凍結乾燥製剤およびその製造方法 |
WO2013108235A1 (en) | 2012-01-20 | 2013-07-25 | Lupin Limited | Stabilized pth formulation |
JP2015504087A (ja) | 2012-01-20 | 2015-02-05 | ルピン・リミテッドLupin Limited | 安定化pth製剤 |
JP2017061424A (ja) * | 2015-09-25 | 2017-03-30 | ニプロ株式会社 | 液体組成物及び凍結乾燥製剤 |
Non-Patent Citations (9)
Title |
---|
HARIPADA ET AL., CURRENT PHARMACEUTICAL BIOTECHNOLOGY, vol. 10, 2009, pages 761 - 766 |
IZUTSU ET AL., JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 95, no. 4, 2006, pages 781 - 789 |
MERRIFIELD, ADVANCES IN ENZYMOLOGY, vol. 32, 1969, pages 221 - 296 |
ROBINSON ET AL., PROC. NATL. ACAD. SCI. USA, vol. 98, no. 8, 2001, pages 4367 - 4372 |
SALGIN ET AL., INTERNATIONAL JOURNAL OF ELECTROCHEMICAL SCIENCE, vol. 7, 2012, pages 12404 - 12414 |
SUMMARY OF LECTURES OF ANNUAL MEETING OF THE SOCIETY OF NIPPON PHARMACOLOGY, 118TH ANNUAL MEETING, vol. 4, 1998, pages 34 |
TAKAI ET AL., PEPTIDE CHEMISTRY, 1979, pages 187 - 192 |
TYLER-CROSS ET AL., JOURNAL OF BIOLOGICAL CHEMISTRY, vol. 266, no. 33, 1991, pages 22549 - 22556 |
VLASAK ET AL., MABS, vol. 3, no. 3, 2011, pages 253 - 263 |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2021117735A1 (ja) * | 2019-12-09 | 2021-06-17 | 旭化成ファーマ株式会社 | テリパラチド又はその塩を含有するプレフィルドシリンジまたはカートリッジ製剤の振盪による白濁を抑制する方法 |
JP6965474B1 (ja) * | 2019-12-09 | 2021-11-10 | 旭化成ファーマ株式会社 | テリパラチド又はその塩を含有するプレフィルドシリンジまたはカートリッジ製剤の振盪による白濁を抑制する方法 |
JP2021178830A (ja) * | 2020-05-11 | 2021-11-18 | 旭化成ファーマ株式会社 | テリパラチド又はその塩を含有する安定な液状医薬製剤 |
JP7147020B2 (ja) | 2020-05-11 | 2022-10-04 | 旭化成ファーマ株式会社 | テリパラチド又はその塩を含有する安定な液状医薬製剤 |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6634175B2 (ja) | 安定性に優れるテリパラチド含有液状医薬組成物 | |
BRPI0921429B1 (pt) | Formulação farmacêutica liofilizada estável, e, método para preparar um fator liofilizado estável | |
JP4751993B2 (ja) | シンカリド製剤 | |
US20220096414A1 (en) | Levothyroxine liquid formulations | |
JPWO2017164349A1 (ja) | PEG化抗ヒトNGF抗体Fab’フラグメント含有医薬組成物 | |
JP7147020B2 (ja) | テリパラチド又はその塩を含有する安定な液状医薬製剤 | |
WO2019176239A1 (ja) | 容器充填ヒトpth(1-34)液体医薬組成物及びその製造方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
ENP | Entry into the national phase |
Ref document number: 2018558440 Country of ref document: JP Kind code of ref document: A |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 18859204 Country of ref document: EP Kind code of ref document: A1 |
|
ENP | Entry into the national phase |
Ref document number: 3075977 Country of ref document: CA |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
ENP | Entry into the national phase |
Ref document number: 2018859204 Country of ref document: EP Effective date: 20200422 |